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his mother, took her hand and said simply, "C'est fini, Maman...". The circumstances 
of his death that night, and the birth of my son two years later, led me to embark on 
this research. 
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Abstract 
__________________________________________________________ 
 
Haemodynamic instability is common during critical illness when homeostatic 
mechanisms are attenuated or already at the limit of their efficacy. Intubation is a 
crucial life-saving intervention which seeks to stabilize respiratory and 
cardiovascular function, but itself represents an additional, short-term haemodynamic 
challenge.   
 
This thesis aimed to investigate changes in heart rate during intubation of critically ill 
children.  Heart rate was chosen as a crude measure of haemodynamic stability 
because it is most readily available even in time-critical pre-hospital settings. 
Focusing on heart rate also raised the question of the benefits of atropine pre-
medication 
 
The first study was an international survey of Paediatric Intensivists using the Delphi 
methodology. There was agreement that there is a risk of death during intubation.  
There was no agreement about the capacity of atropine to reduce the incidence of 
bradycardia, hypotension or death. 
 
An observational study of 414 intubations in critically ill children was used to 
provide data for the thesis. Reductions in heart rate were common amongst first 
intubations in neonates, children between 28 days of age and eight years and further 
intubations in both groups. The limitations of using the minimum heart rate as a 
measure of haemodynamic disturbance were considered. An alternative measure of 
the change in heart rate, or ‘lost-beats’, was proposed and investigated. Atropine use 
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was associated with less of a fall in heart rate and fewer lost heart beats during 
intubation.  
 
There was a strong association between a low heart rate and an increased incidence 
of arrhythmias and conduction abnormalities during intubation. Arrhythmias and 
conduction abnormalities were reduced, but not eliminated, by atropine pre-
medication. Sinus tachycardia was not observed to convert to ventricular tachycardia 
or fibrillation when atropine was used. 
 
Mortality during critical care intubation was low (<0.5%).  Atropine could not be 
statistically proven to have an effect on mortality during intubation although was 
associated with reduced intensive care mortality in children over 28 days of age but 
not in neonates.  The association of atropine pre-medication with reduced PICU 
mortality in children over one month is unexpected and requires further 
investigation. 
 
A rabbit model of endotracheal intubation was used to investigate the consequences 
of vagal activation on blood pressure in hypovolaemia and endotoxaemia. 
Hypovolaemic rabbits observed a significantly smaller decrease in blood pressure 
after vagal stimulation than that in control rabbits. The relative change in blood 
pressure after vagal stimulation was similar between the endotoxaemic rabbits and 
controls. This finding suggests that different disease states may influence the 
haemodynamic function during intubation. 
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Chapter One 
Introduction 
__________________________________________________________________ 
 
"The time has come when Belladonna drugs should be tailored to  
circumstance and not given by rote" Eger 1962(1) 
 
'...[the] long-term benefits and adverse effects  
of [atropine] premedication are unknown'. Kumar et al. 2010(2) 
 
 aemodynamic instability is common during critical illness. Patients with                       
reduced cardio-respiratory reserve may deteriorate further during induction of 
anaesthesia and intubation.(3, 4) This risk of deterioration relates not only to 
respiratory factors such as loss of lung volume or risk of aspiration but to loss of 
acute haemodynamic compensatory mechanisms. Myocardial depressant(5) or 
vasodilatory effects(6) of induction agents and vagally-mediated responses to 
hypoxia(7) and/or laryngoscopy(8-10) may all add to the risk of haemodynamic 
decompensation during intubation. 
 
A degree of haemodynamic instability is encountered frequently during routine 
anaesthesia and is well-tolerated.(11-13) During critical illness many of the 
haemodynamic homeostatic mechanisms are attenuated or already at the limit of their 
efficacy. Hence a relatively minor additional insult may have dramatic consequences. 
It is a paradox that critical care intubation often takes place to support 
haemodynamic function yet itself represents a haemodynamic challenge. The APLS 
'Golden Hour' Handbook lists 'haemodynamic unstable or hypotensive patients' as 
H 
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being candidates for intubation.(14) Ironically it also lists 'hypotension, and  
bradycardia' as being complications of intubation.(15)  
 
Adult studies of intubation in critical care settings describe a mortality risk of up to 
3%, with prior hypotension being an important associated risk factor (3, 16, 17) and 
intra-intubation bradycardia being a risk for cardiac arrest.(18) In contrast, studies in 
critically ill children to date have limited themselves to describing bradycardia.(19-
21) As such we do not know the incidence of fatal deterioration during intubation of 
critically ill children or the associated risk factors.   
 
One of the many factors contributing the intubation risk has long been thought to be 
readily amenable to treatment. Unwanted efferent vagal discharges in response to 
hypoxia and/or laryngoscopy can effectively be blocked by inhibition of muscarinic 
acetylcholine action. In the 1950’s the use of the ‘vagolytic’ drug atropine, as part of 
induction pre-medication, was proposed specifically to attenuate bradycardia which 
was often associated with the use of suxamethonium or other relatively cardio-toxic 
inhalation anaesthetic agents, such as halothane.(22, 23) The subsequent transition 
away from suxamethonium to less toxic drugs, such as sevoflurane and non-
depolarising muscle relaxants, led anaesthetists to question the continued usefulness 
of atropine.(24-27) Today, the use of atropine has been almost entirely abandoned 
for routine paediatric pre-medication.(28)  
 
In contrast to the reduction in use of atropine for routine anaesthetic intubation, 
atropine has been recommended in recent years for use during critical care 
intubations in neonates(29-32), children under five years (31, 33) and for children in 
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septic shock.(34) These recommendations exist in the absence of studies assessing at 
the impact of atropine on heart rate, haemodynamic instability, or outcomes in 
critically-ill children.(35) In 2010, Kumar et al. published a review of premedication 
for non-emergency intubation in the neonate and noted amongst the 'gaps in 
knowledge' that, '...[the] long-term benefits and adverse effects of [atropine] 
premedication are unknown'.(2)  
 
1.1  Definition of 'Critical Care Intubation' 
The term 'critical care intubation' is used during the extent of this thesis, as opposed 
to 'emergent' or 'urgent' intubation which deal with the relative rapidity with which 
the intubation should be performed.(19) The study seeks to demonstrate the effects of 
intubation on haemodynamic stability during an episode of critical care illness.  
 
1.2  Aims of the study 
The general aim of this thesis is to describe the nature and effects of haemodynamic 
disturbance, with a focus on heart rate and blood pressure, during intubation of 
critically ill children and to examine the factors that contribute to instability. 
 
Specifically, the aims of this thesis were to  
1 establish the perceived frequency of haemodynamic disturbances during 
 intubation among a group of peers and the factors that influence the 
 prescription of atropine. 
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2 describe the range of normal and abnormal heart rates during critical care 
 intubation. 
3 describe the incidence of arrhythmias after atropine administration and during 
 intubation. 
4 describe the mortality rate during intubation and the association with atropine 
 use. 
4 test the hypothesis that hypovolaemia and endotoxaemia have no effect on 
 haemodynamic instability during vagal stimulation in an animal model of 
 intubation. 
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Chapter Two 
Background 
____________________________________________________________________ 
 
2.1 A Short History of Critical Care Illness in Neonates and Children 
 
The treatment of premature infants, or 'faibles', often translated as 'weaklings', was 
introduced in 1898 by Pierre-Constant Budin and other centres opened from 1914 
onwards in North America and Western Europe.(36) Pierre-Constant Budin's 
achievement was the insistence of using maternal milk sometimes using a feeding 
tube. Although pathological specimens of neonatal respiratory distress syndrome 
(RDS) exist from as early as 1903, the clinical syndrome was not described until 
1932.(37) Mechanical ventilation for RDS did not occur until the 1960's. Exchange 
transfusion was performed for jaundice and erythroblastosis from 1925 and in 1946 
canulation of the umbilical vein was performed for the purposes of exchanging 
blood.(36) A necessary step in the treatment of the smaller newborns was the 
maintenance of temperature homeostasis using an incubator which appeared in 
Boston, USA, shortly before the Second World War.(36) 
 
 
 
 
29 
 
Figure 2-1; Dr. Pierre-Constant Budin (1846-1907), obstetrician and paediatrician 
who pioneered the treatment of premature and small-for-dates newborns. (This image 
was obtained from http://www.neonatology.org/pinups/budin.html on 17.07.2012). 
The advent of specialist units for the treatment of surgical disease in older children 
occurred in the 1950's when Everett Koop realised that post-operative care in general 
surgical wards was insufficient to ensure survival.(36) The foundations of paediatric 
cardiac surgery were laid just before the Second World War following the repair of a 
patent ductus arteriosus by Gross (38) and the relief of Tetralogy of Fallot by the 
Blalock-Taussig shunt just after the war.(39) 
 
Specialist units for the care of children were established by anaesthetists from the 
mid-1950's. In Paris the Hôpital St. Vincent de Paul and in England Alder Hey 
Children's Hospital were amongst the first.(36) The Hôpital St. Vincent de Paul, 
where some of the children included in this thesis were hospitalised, has just closed. 
G. Jackson Rees at Alder Hey introduced the concept of 'convalescent' beds and 
'resuscitation' beds that were equipped for general anaesthesia.(36) 
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Today, the treatment of life-threatening illness in an expanded network of intensive 
care units in developed, and some developing, countries has been one of the major 
achievements of modern paediatrics. Diseases that were hitherto regarded as 
incurable are now amenable to therapy with ventilatory, haemodynamic support and 
‘blood purification’. Survival continues to improve.(40) Overall PICU mortality in 
the United Kingdom and Ireland was 5.5% in 2003-2004 and 4.2% in 2008-
2010.(41)  
 
2.2  A Historical Perspective of Intubation 
 
The use of the trachea for respiration bypassing the upper airway is by no means a 
recent phenomenon. Tracheotomy was recorded as having been performed to 
alleviate an acute obstruction of the upper airway in extremis in ancient Egyptian 
writings of around 3500BC.(42) Emergency tracheotomy has also been described in 
ancient Arabic(43), Indian(44) and Greek literature.(45) Alexander the Great is 
credited with having saved the life of an injured soldier on the battlefield by 
performing an emergency tracheotomy with his sword.(46)  
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Figure 2-2; Alexander the Great at the Battle of Issus in when the young Alexander 
defeated King Darius III of Persia in 330BC in the struggle for power in Asia. (This 
image was obtained from http://www.cliolamuse.com/spip.php?article1 on 17.07.2012). 
Asclepiads of Bithynia supposedly carried out a non-emergency tracheotomy (45) 
and Galen of Pergamum performed artificial ventilation, using a bellows on a dead 
pig.(47) Without doubt the Renaissance played an essential role both in changing 
attitudes to, and knowledge of the human body. The practice of dissection provided 
the knowledge regarding the anatomy and often the physiology of the body. Andreas 
Vesalius (1514-1564AD) was responsible for the first serious textbook of anatomy 
first published in 1543, De humani corporis fabrica.(48) Indeed, it was Vesalius who 
is credited with the idea of tracheal intubation to facilitate ventilation when he 
inserted a reed into the trachea through a tracheotomy of a dying pig into which he 
intermittently blew.(47, 49)  
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Figure 2-3; Andreas Vesalius (1514-1564AD) (left) published the first serious 
textbook of anatomy in 1543, De humani corporis fabrica. On the right is a feature 
of one of his anatomical studies showing details of the musculature of the torso and 
neck. (This image was obtained from https://www.google.fr/search?q=Andreas+Versalius 
+image&hl=fr&prmd=imvnso&tbm=isch&tbo=u&source=univ&sa=X&ei=X9YGUP3kLsel0AWzjvz
DDQ&ved=0CF4QsAQ&biw=1366&bih=650 on 17.07.2012). 
  
 
The first serious study of tracheotomy was published by Armand Trousseau who 
described a series of 169 cases in 1852.(50) Many of the patients from whom data 
were collected for this thesis were hospitalised at the Hôpital Armand Trousseau in 
the XII
e
 arrondissement in Paris. 
 
Tracheal intubation using the oro-pharyngeal route probably originated in the mid 
1700's when the Chelmsford surgeon Benjamin Pugh inserted a leather-covered 
coiled wire tube, or 'air-tube', into the trachea and performed intermittent insufflation 
on an asphyxiated new-born. Later, in 1807, Chaussier produced a curved rigid metal 
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canula for insertion into the trachea into which he blew.(49) Both of these pioneers 
were unable to see the tracheal orifice. 
 
Figure 2-4; Armand Trousseau (1801-1867) is credited, amongst other 
achievements, with being the first physician in France to perform a tracheotomy. 
Note the striking resemblance between Armand Trousseau the young Alexander the 
Great in Figure 2.2. (This image was obtained from 
http://en.wikipedia.org/wiki/Armand_Trousseau on 17.07.2012). 
 
 
The creation of a device enabling direct visualisation of the laryngopharynx was 
essential to allowed oro- or naso-tracheal intubation to be repeated with 
reliability.(51) However, progress in the techniques of intubation and ventilation 
would have been insufficient without parallel evolution in the efficacy and delivery 
of volatile anaesthetics (from the Greek meaning without sensation, αν-, an-, 
'without' and αἴσθησις, aisthēsis, 'sensation'). Mechanical ventilation using 
humidified gases at a constant tidal volume was introduced by Prof. Trendelenberg in 
1910 in Leipzig, Germany.(36) 
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Magill advanced the process of intubation by introducing a laryngoscope blade 
which enabled the passing the endo-tracheal tube alongside the laryngoscope (52-54) 
The curving the blade of the laryngoscope, which is so well recognised today was 
made popular by Macintosh in 1943.(55),  
 
The transfer of anaesthetic skills from the operating theatre to the ward for the 
provision of chronic respiratory support dated from 1940's and 50's. Björn Ibsen 
made available chronic respiratory support through tracheotomies for suffers of polio 
by using medical students to give positive ventilation. Negative pressure ventilation 
using 'iron lungs' was also employed.(36) Ibsen later commented in an interview, 
'what we did was just to use the principles and techniques, which served us well in 
the operating theatre, also on patients with medical diseases'.(56) 
 
Volatile anaesthetics have several disadvantages that make them unsuitable from the 
point of view of their use during critical illness. These are principally the equipment 
entailed in their vaporisation and their flammable nature when eliminated. As such, 
the act of intubation remained the domain of the operating theatre. It required the 
development of liquid anaesthetics, metabolised rather than excreted by the body, to 
enable tracheal intubation to take place outside theatre.  
 
2.3  Injectable induction drugs 
 
The barbiturate thiopental was discovered in the 1930's.(57) Thiopental is an 
unsatisfactory anaesthetic because of its limited analgesic qualities (57) and negative 
inotropic properties.(12) It is for this reason that thiopental is frequently administered 
with a morphine based drug. The NMDA (N-methyl-D-aspartic acid) receptor 
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antagonist ketamine was discovered in 1962.(58) One of the advantages of ketamine 
is that it is a good analgesic. Ethomidate was discovered in 1960's, and effectively 
induces amnesis, but again is not a good analgesic.(59) Finally, the powerful 
hypnotic propofol was first marketed as an emulsion by the then ICI in 1986. 
 
Figure 2-5; Molecular structures of A, thiopental, B; ketamine and C; ethomidate. 
(These images were obtained from http://en.wikipedia.org/wiki/File:Sodium_thiopental.svg, 
http://en.wikipedia.org/wiki/Ketamine and http://en.wikipedia.org/wiki/Etomidate on 17.07.2012). 
               Thiopental                      Ketamine                       Etomidate 
     
 
The combination of anaesthetic agents for 'induction' of anaesthesia and intubation 
followed by sedation with drugs such as morphine meant that patients could be 
intubated and ventilated in a pain-free manner.  
 
The most widely used sedative agents are the opiates morphine and its modern day 
fast-acting morphine derivatives (such as sufentanil, fentanyl and remifentanil), all of 
which are effective analgesics. Morphine (from the Greek god of dreams, Morpheus-
Μορφέας) is extracted from the latex (opium) derived from the excoriation of poppy 
seed pods by Friedrich Sertürner in 1804.(60) Morphine is the primary biological 
constituent of opium and has analgesic properties in relieving the discomfort of the 
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ETT and inducing a sensation of euphoria, both of which assist coordination with 
mechanical ventilation.  
 
Figure 2-6; Poppy (Papaver somniferum) seed pod, left showing the latex containing 
opium and, right, field of poppy in June 2000, Farah Province, Afghanistan. (The 
image on the left comes from the Author's collection and that on the right was obtained from 
https://www.google.fr/search?q=picture+poppy+seed+pod&hl=fr&prmd=imvns&tbm=isch&tbo=u&s
ource=univ&sa=X&ei=_h0JULDmLJSYhQeWjvnvCQ&ved=0CFMQsAQ&biw=1366&bih=650#hl=
fr&tbm=isch&sa=1&q=picture+poppy+seed+pod+opium&oq=picture+poppy+seed+pod+opium&gs_
l=img.3...64299.65847.0.66123.6.6.0.0.0.0.173.648.4j2.6.0...0.0...1c.enBZYjF0RvU&bav=on.2,or.r_g
c.r_pw.r_qf.,cf.osb&fp=9104bee40e719afc&biw=1366&bih=650 on 20.07.2012). 
         
 
Figure 2-7; Molecular structures of morphine and the derivatives fentanyl and 
sufentanyl. (Thse images were obtained from http://en.wikipedia.org/wiki/Morphine, 
http://en.wikipedia.org/wiki/Fentanyl and http://en.wikipedia.org/wiki/Sufentanil on 20.07.2012). 
        Morphine                              Fentanyl                                  Sufentanyl 
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2.4  Rapid Sequence Induction 
 
Injectable anaesthetics may insufficiently protect from pain and involuntary muscle 
tension which may make securing the airway uncomfortable and difficult. The 
solution was to give a separate paralysing drug in association with the anaesthetic 
drug. When combined with an injectable anaesthetic outside theatre the phase of 
ventilation and oxygenation is dispensed with and the intubation becomes one of 
'rapid sequence', or rapid sequence induction of anaesthesia for intubation (RSI). 
Rapid Sequence Induction involves several steps; pre-oxygenation, pre-medication, 
muscle relaxation and induction, intubation, primary and secondary confirmation and 
post-intubation patient management.(61) The technique of RSI has been successfully 
extended to neonates.(32, 62, 63) 
 
2.4.1  Depolarising muscle relaxants 
Suxamethonium was derived from the unsatisfactory decamethonium in 1949.(64) 
Suxamethonium is a non-competitive agonist of acetylcholine on the post-synaptic 
membrane of nicotinic synapses in muscle which it depolarises before blocking. The 
structures of acetylcholine and suxamethonium are illustrated in figure 2-8. 
Acetylcholine is metabolised in fractions of a second whereas the onset of action and 
elimination of suxamethonium is in the order of 2-4 minutes.(65) Elimination takes 
place through the activity of the plasma enzyme butyrylcholinesterase and is 
substantially slower than the metabolism of acetylcholine by acetylcholinesterase.  
 
Suxamethonium was introduced for intubation in theatre. A volatile anaesthetic was 
administered by manual ventilation with oxygen and then the muscle relaxant 
38 
 
injected prior to intubation. This technique ensured that the patient was both 
compliant with, and remembered nothing of, the procedure of intubation. 
 
The principal advantage of RSI is that the patient will awaken rapidly. This means 
that the patient can ensure his own ventilation in case of failure of intubation. Rapid 
sequence induction is frequently performed in combination with cricothyroid 
pressure which is supposed to reduce the risk of vomiting and inhalation pneumonitis 
during intubation, although this last point is disputed.(66)  
 
Figure 2-8; Molecular structures of acetylcholine and suxamethonium. (These images 
were obtained from http://en.wikipedia.org/wiki/Suxamethonium and http://en.wikipedia.org/wiki/ 
Acetylcholine on 17.07.2012). 
 
              Acetylcholine                                      Suxamethonium 
              
 
Suxamethonium has rapid onset and rapid inactivation but it is not without its 
disadvantages. The most notable side effects are related to the massive depolarisation 
of skeletal muscle synapses prior to their inactivation. This provokes an acute rise in 
plasma potassium concentration, which may have effects on myocardial function and 
can cause muscle pain following awakening.(67) Malignant hyperthermia is a serious 
secondary effect and is related to a group of autosomal dominant genes.(67) A 
separate class of neuromuscular blocking drugs was being developed over the same 
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time which would not possess the side-effects of the depolarising muscle relaxants; 
the curares. 
 
2.4.2  Non-depolarising muscle relaxants 
The curares are a mixture of alkaloids that were initially derived from 
Chondodendron tomentosum, a South American plant used by Indians when hunting 
to paralyse their prey.(68) D-tubocurarine was isolated in 1935 with the synthetic 
atracurium being produced later.(69) All of the curares are quaternary compounds 
which means that they are poorly absorbed and rapidly excreted. They compete at the 
post-synaptic acetylcholine receptor, as does suxamethonium, but are non-
depolarising. Their secondary effects are that of ganglion blocking and occasional 
hypersensitivity reactions.(70, 71) Both of which potentially reduce blood 
pressure.(68) Nevertheless, hypersensitivity reactions to suxamethonium remain 
more frequent than for the curares.(71) Some disadvantages of the curares are that 
their onset and duration of action are relatively longer than that of 
suxamethonium.(68) Another disadvantage of the curares compared to 
suxamethonium is that the onset of paralysis with suxamethonium is accompanied by 
visible muscle fasciculation at the end of which the muscles will be in a state of 
paralysis. Despite this, atracurium is of relatively short action and the technique of 
Inverse Sequence Induction (ISI) has been developed as an alternative to RSI. In ISI, 
atracurium is given before the anaesthetic which means that the onset of action of the 
two drugs is coordinated.(72, 73) The structures of tubocurarine and atracurium are 
illustrated in figure 2-9. 
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A recent Cochrane Review noted that both suxamethonium and rocuronium provided 
excellent intubating conditions; suxamethonium was slightly preferable to 
rocuronium.(74)    
 
Figure 2-9; Molecular structures of tubocurarine and atracurium. (This image was 
obtained from http://en.wikipedia.org/wiki/Tubocurarine and http://en.wikipedia.org/wiki/Atracurium 
on 20.07.2012). 
              Tubocurarine                                            Atracurium 
       
 
2.5  Intubation in Specific Critical Care Scenarios 
 
Individuals with a variety of pathologies can benefit from intubation and ventilation. 
Globally these can be divided into the following organ systems; respiratory tract, 
nervous system and circulation. Sometimes the failure of several organ systems, 
multi-organ dysfunction syndrome (MODS) may require ventilation. Ventilation for 
neurologic impairment aims to protect the airway and ensure constant respiration, 
whereas ventilation for respiratory and circulatory failure aims to optimise gaseous 
transfer and minimise the work of breathing. 
 
2.5.1  Nervous system: Central Nervous System Failure 
Coma (from the Greek meaning deep sleep, koma-κῶμα) is a state of severely 
depressed consciousness arising from inhibition of brain activity. Any reduction in 
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the activity of the mesencephalic portion of the reticular activating system of the 
mid-brain is capable of inducing coma. Diverse types of pathology can induce coma; 
metabolic derangements such as hypoglycaemia, hypothermia, global brain insults 
such as cerebral oedema or specific lesions such as stroke, intoxication, prolonged 
hypoxia and inflammation such as encephalitis. Intubation and ventilation is carried 
out for three separate reasons. Firstly, the same pathophysiologic processes that are 
responsible for the coma may provoke respiratory depression by inhibiting the 
respiratory centre that is located in the brain stem. Secondly, inhibition of laryngeal 
reflexes may allow inhalation of the stomach contents during regurgitation.(75) 
Thirdly, there is a risk of severe acute respiratory depression as a result of herniation 
from increases in intra-cerebral pressure. 
 
2.5.2  Respiratory tract 
2.5.2.1 Reduced lung compliance 
Pathologies that reduce lung compliance increase the work of breathing by 
exaggerating the effort required to expand the lungs. This is above and beyond the 
work normally necessary to overcome the natural elastic forces of the parenchyma 
and is expressed in the equation below; 
                   
,...where V is a change in volume and P a change in pleural pressure. 
 
Artificial ventilation reduces the work of breathing which increases efficiency of 
exchange of respiratory gases. Examples of which include respiratory distress 
syndrome (RDS - previously known as hyaline membrane disease due to its 
Compliance  = 
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histopathological appearance) of the newborn infant where surfactant is 
deficient,(76) infection, pulmonary oedema and lower airway obstruction such as in 
asthma. 
 
2.5.2.2 Airway resistance 
The work required to overcome airway resistance can be increased by any narrowing 
of the airway or airways whether these be in the upper airway. Relatively small 
constrictions may produce large disturbances in flow even when turbulent flow is not 
precipitated. Resistance in the airways is governed by Poiseuille's law. 
 
2.5.4  Circulation 
2.5.4.1 Cardiogenic Shock 
Pump failure may occur due to a variety of reasons whether they are related to 
muscle malfunction, interruption of the conduction system or abnormalities of the 
valves or pericardium. Heart failure can be divided into dilated and hypertrophic 
causes. The most frequent causes of dilated heart failure in a recent North American 
study are idiopathic, myocarditis, malformation syndromes and inborn errors of 
metabolism The principal causes of hypertrophic heart failure are inborn errors of 
metabolism and malformation syndromes.(77) Geographical variation may have an 
important influence on epidemiology of heart failure with Kawasaki disease being 
more common in Japan (78) and typhus in India.(79) 
 
Anatomical defects may create the conditions necessary for a hyperdynamic 
circulation whereby rapid transfer of blood occurs between the venous and arterial 
compartments.  
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The most frequent initial treatment of heart failure is off-loading of the left ventricle 
by the use of diuretic. Thereafter digoxin and/or inotropic support may be 
necessary.(77) The long term survival of children with acute fulminating myocarditis 
has been associated with the left ventricular ejection fraction on arrival at 
hospital.(80)  
 
2.5.4.2 Septic Shock 
Septic shock occurs due to disseminated infection in the vasculature. Septic shock 
causes widespread depletion of anti-oxidants and mitochondrial dysfunction which is 
a risk for multi-organ dysfunction syndrome.(81, 82) The classical description of 
septic shock involves the production of endotoxin by gram-negative bacteria which 
can bring about agglutination of platelets, fever, high cardiac output and particularly 
prolonged capillary refill time and hypotension due to vasodilatation.(34, 83, 84) The 
physiological deficits present in septic shock are a reduction in pre-load, and a 
reduction in left ventricular stroke volume.(85) Early septic shock in the USA is 
associated with 5-7% mortality with those in established shock having a mortality is 
as high as 30%.(86) Established haemodynamic disturbance during bacterial 
meningitis is a risk factor for early mortality.(87) The treatment is through early 
volume boluses and noradrenaline which correct pre-load and myocardial 
contractility deficiencies.(88)  
 
2.5.4.3 Hypovolaemic Shock 
Several diverse conditions can be responsible for hypovolaemic shock. There may be 
loss of volume as during haemorrhage of blood, loss of water due to vomiting or 
excessive sweating or loss of plasma as a result of burns. The haemodynamic 
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response to hypovolaemia depends on the rate of loss of volume. During acute 
haemorrhage the haemodynamic response is biphasic and asymmetric with the early 
phase consisting of maintenance of blood pressure in the face of a decrease in cardiac 
output due to a reduction in left ventricular ejection volume. This can only be 
achieved by an increase in systemic vascular resistance.(89) The second phase is 
characterised by falling blood pressure despite a maintenance of cardiac output and is 
a result of a decrease in systemic vascular resistance.(90, 91) 
 
2.6  A very brief Introduction to Haemodynamics 
The heart acts as a pump by its force of contraction. The rate of contraction and 
volume of blood ejected during each cycle (stroke volume) are equal to the cardiac 
output (ml/min). 
  
Cardiac output = stroke volume * heart rate 
 
The vascular resistance to the blood injected into the arterial compartment of the 
circulation generates blood pressure (mmHg). Both resistance (dyn/cm
2
) and 
pressure are proportional to one another.  
 
Blood pressure = Cardiac output * Resistance 
 
Pressure is only a potential for movement of blood. Flow is permitted by a pressure 
gradient, as is described in Ohm's law. Resistance is the principal factor influencing 
differential pressure and therefore flow, assuming equal viscosity. 
 
Flow =  Change in pressure 
             Resistance 
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The circulation of blood can be described in two manners; linear, equivalent to 
velocity (cm/s) or flow, which is a specified volume over a period of time (cm3/s). 
Velocity is dependent on the physical properties of the fluid, pressure gradient and 
the dimensions of the system in which flow is occurring. There is an inverse 
relationship between flow and the cross sectional area of the tube in which blood is 
passing. According to Poiseuille's law (the hydraulic resistance equation) the rate of 
flow is inversely proportion to the power of four of the radius of the airway, and 
assuming unchanged viscosity.(92) 
 
                             
...,where n = viscosity, l = length and r = radius. 
 
It is important to note that an increase in heart rate or ejection volume will have a 
linear effect on cardiac output, whereas, according to Poiseuille's law, any change in 
the radius of the vessels will have an exponential effect on blood flow (assuming that 
viscosity remains constant).  
 
There are several means by which the body modifies blood flow; by variation in 
ejection volume, heart rate and/or vascular resistance. The regulation of all three is 
dependent on the dynamic relationship between the autonomic nervous system and 
humeral influences. The reaction of the body to hypotension is to attempt to increase 
cardiac output by increasing vascular resistance, ejection volume and heart rate. 
These changes are in part mediated by the secretion of catecholamine hormones 
(principally adrenaline and to a lesser extent noradrenaline) from the adrenal medulla 
Resistance to flow  = 
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which can act on the vasculature and heart. An increase in vascular resistance is also 
mediated by the sympathetic nervous system which acts locally using noradrenaline 
as a neurotransmitter. 
 
2.7  Control of the Circulation 
 
The autonomic nervous system (ANS) is divided into sympathetic and 
parasympathetic branches. The ANS effectuates the communication between the 
vasomotor centre situated in the midbrain and the nervous and humeral mechanisms 
that regulate blood flow.  
 
2.7.1  The vasomotor centre 
The vasomotor centre consists of an area which controls vascular constriction and 
dilatation and a sensory area. It is to be found in the reticular substance of the 
medulla and lower third of the pons.(93) Continuous firing of the vasoconstrictor 
area is responsible for vascular tone. Hypothalamic and cortical influences are 
integrated in the vasomotor centre. Heart rate is controlled by the parallel influences 
of the lateral portions of the vasomotor centre via sympathetic nerves to the heart. 
These increase heart rate and contractility whilst the medial portions, in immediate 
juxtaposition to the dorsal motor nucleus, control the parasympathetic Vagus 
nerve.(93)  
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2.7.2  The parasympathetic nervous system control of the heart; the Vagus 
  nerve 
The Vagus is the X
th
 cranial nerve whose name is derived from the Latin for 
'wandering'. Activation of the Vagus nerve reduces the heart rate by reducing the 
periodical discharge of the sino-atrial node (SAN) which is responsible for the 
control of heart rate. The SAN is the phylogenic remnant of the sinus venosus of 
lower vertebrate hearts and is situated in the right atrial wall near the insertion of the 
superior vena cava. Regular spontaneous depolarisations of the cell membranes of 
the SAN trigger an action potential when an electrophysiological threshold is passed. 
This activity has often been described as a pacemaker.(94) These depolarisations are 
conducted through the atrioventricular node along the Purkinje fibres to the apex of 
the ventricles and ensure rhythmic, coordinated contraction of the heart.  
 
The Vagus also transmits afferent sensory fibres from the aortic bodies that are 
activated by decreases in oxygen tension and tactile stimulation from the larynx by 
the superior laryngeal nerve. Particular amongst the cranial nerves the Vagus has 
both afferent and efferent fibres. It is this quality whereby sensory information and 
motor responses are transmitted by the same nerve which allows the vagal activation 
to be described as 'reflex'. 
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Figure 2-10; The anatomy of the Vagus nerve showing afferent sensory fibres from 
the superior laryngeal nerve and efferent fibres of the cardiac branch which innervate 
the sino-atrial node. (This image was obtained from 
https://www.google.fr/search?q=image+anatomy+vagus+nerve&hl=fr&prmd=imvns&tbm=isch&tbo
=u&source=univ&sa=X&ei=CFsJUP6pGcOR0AWMwJWuCg&ved=0CFoQsAQ&biw=1366&bih=6
50#hl=fr&tbm=isch&sa=1&q=image+vagus+nerve&oq=image+vagus+nerve&gs_l=img.3...302178.3
02178.0.302363.1.1.0.0.0.0.150.150.0j1.1.0...0.0...1c.t8yE9XAnG3U&bav=on.2,or.r_gc.r_pw.r_qf.,cf
.osb&fp=9104bee40e719afc&biw=1366&bih=650 on 20.07.2012). 
 
 
2.7.3  Reflex bradycardia : hypoxia. 
Hypoxia in the aortic bodies provokes reflex bradycardia which probably developed 
as a survival mechanism by early aquatic organisms that needed to cope with 
currents of hypo-oxygenated water. Primitive organisms which were dependent on 
oxygen for cellular respiration were obliged to match metabolism to oxygen supply. 
Later in evolution the same reflex bradycardia protected fish from oxygen 
deprivation during the temporary collapse of their gills during terrestrial 
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exploration.(95) Reflex bradycardia is strongly conserved in many animal species 
and persists in crabs,(96) trout,(97) carp,(98) sturgeons(99) and is enhanced to deal 
with a return to water by amphibious and diving animals such as frogs(100, 101), 
turtles(102), ducks(103, 104), elephant seals (105) including armadillos 
experimentally covered in soil.(106) 
 
We find the same reflex again exploited by certain mammals to adapt circulatory and 
metabolic needs during the early euthermic stage of hibernation.(107) It is also 
interesting to note that both tubocurarine and atropine, a selective antagonist of 
acetylcholine in muscarinic receptors, are both produced by plants. Acetylcholine is 
also used in non-neuronal cell transmission and these two observations demonstrate 
the usefulness of acetylcholine in diverse biological systems.(108) 
 
The capacity to induce reflex bradycardia is retained by terrestrial mammals (109) 
including human children (7) and adults during diving (110, 111) and sleep apnoea 
(112) probably as an evolutionary vestige. Prior to birth and during the first three to 
six months of life humans possess an autonomic imbalance due to the dense Vagal 
innervation of the sino-atrial node and poor sympathetic innervation of the ventricles 
and conduction bundles.(113) This disequilibrium allows the fetus to mount a defence 
against the hypo-oxygenation due to the placental hypoperfusion which accompanies 
contractions during birth. A further manifestation of this is the higher frequency of 
reflex bradycardia in the young during routine anaesthetic intubation.(4)  
 
Vagally mediated bradycardia is ‘compensated’ by the selective vasoconstriction of 
non-vital organs by the vasomotor centre.(95, 114-118) The overall effect is one of 
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redistribution of blood flow to maintain availability of oxygen to the brain (119) and 
other vital organs whilst generally reducing metabolite consumption in general (120, 
121) and cerebral metabolism in particular.(122) 
 
Free divers exploit the Vagus nerve to depress their heart rate, increase peripheral 
vasoconstriction and decrease cardiac output all of which aid conservation of oxygen 
during prolonged submersion.(110, 111, 123, 124) Ventricular escape beats have 
been observed during episodes of severe bradycardia.(111, 125) It is interesting that 
there may be a component of neuro-humeral adaptation to repeated episodes of 
prolonged hypoxia.(110) 
 
Individuals with high cervical cord lesions, generally acquired through injury, have 
exaggerated bradycardia when sensory afferent vagal fibres are stimulated. This is 
because unbalanced parasympathetic activity is exerted on the heart by the 
interruption of transmission between the vasomotor centre and the sympathetic 
ganglia. During tracheal aspiration or hypoxia severe bradycardia occurs that can 
sometimes stop the heart.(126, 127) When both the Vagus and sympathetic 
innervations to the heart are abolished following heart transplant, the bradycardia 
associated with desaturation during sleep apnoea is abolished.(128) 
 
It is possible that certain individuals may have an innate, exaggerated vagal reflex, or 
perhaps in sufficient sympathetic tone, due to a genetic predisposition. The result is 
that the presence of reflux acid around the vocal cords in some infants may be 
responsible for intense and prolonged bradycardia.(129) It has been suggested that any 
51 
 
such genetic pre-disposition may be associated with sudden infant death syndrome 
(130, 131) or acute life-threatening events.(132)  
 
The vagal reflex arc has also been postulated to have control over inflammation.(133) 
Several experimental models have suggested that the immune response may be 
modulate by cholinergic neurones in such a way that vagal activation may reduce 
inflammation.  
 
2.7.4  The sympathetic nervous system control of the heart and vasculature 
Unlike the parasympathetic nervous system, which innervates only the heart, the 
sympathetic nervous system has vasomotor fibres in the heart and vessels. These are 
supplied from the upper five or six thoracic and lower one or two cervical segments of 
the spinal cord.(134) Synapses are situated in the paravertebral chains of ganglia the 
middle of which joins a plexus with the Vagus nerve in the mediastinum before 
entering the heart.(134) Fibres from the sympathetic fibres penetrate the heart along 
the coronary vessels before reaching their insertions in the myocardium. Elsewhere in 
the body, all the vessels with the exception of the capillaries, pre-capillary sphincters 
and meta-arterioles are sympathetically innervated.(135) Innervation of the arteries is 
generally responsible for the phenomenon of resistance to flow and innervation of the 
veins is responsible for regulating volume and thus right atrial pressure. 
 
The carotid bodies sense changes in blood pressure and transmit impulses by the 
Glossopharyngeal nerve (the IX
th
 cranial nerve) to the vasomotor centre. These have 
an important influence on sympathetic nervous activity which acts so as to increase 
blood pressure. The actions on the heart include an increase in heart rate and an 
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increase in contractility. In parallel, there is an increase in vascular tone. Both of these 
effects are mediated by the action of noradrenaline on α1 and α2 adrenergic receptors 
situated in post-synaptic membranes of the vasculature and β1 adrenergic receptors 
situated in the heart. 
 
Figure 2-11; Autonomic nervous system control of the circulation showing 
sympathetic innervation of the heart and vessels. The Vagus nerve efferent 
innervation of the heart is also shown.  
 
 
2.7.5  Disease processes may influence autonomic haemodynamic control 
The influence of age on the maturation of the autonomic balance is a feature of the 
normal development of control on the circulation and has been discussed in 
2.7.3.(113) Subsequent autonomic disequilibrium of the autonomic nervous system, 
or dysautonomia, may develop secondarily or as a result of an inherited genetic 
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disorder.(136) Secondary dysautonomia may equally arise from the effects of certain 
diseases. For instance, RDS and prematurity can affect the process of autonomic 
maturation.(137, 138) Generalized brain injury (139) or specifically to the 
sympathetic trunk in the thorax (140) can also generate autonomic imbalance. In 
experimental situations sepsis has been shown to affect baroreceptor activity (141) 
which may be linked to the direct effect of inflammatory cytokines.(142)  
Deleterious clinical outcome has been associated with dysautonomia due to brain 
injury of several causes.(139, 143, 144)  
 
2.7.6  Heart rate variability 
Background heart rate variability results from the dynamic equilibrium of the 
activation of the SAN by the Vagus nerve, which is almost instantaneous, and by the 
relative slowness of the sympathetic nervous control, which is in the order of a few 
seconds. Efferent vasomotor fibres are contained in the Vagus nerve, which uses 
acetylcholine as a neurotransmitter, and the sympathetic nerves of the autonomic 
system, that uses noradrenaline as a neurotransmitter. There are very different 
response times built into the two systems. Acetylcholine is stored in vesicles and is 
released in sufficient quantities to stop the heart within one cardiac cycle. The 
metabolism of acetylcholine in the synaptic left is by the enzyme 
acetylcholinesterase and proceeds in the order of milliseconds. Whereas, the release 
of noradrenaline is mediated by the secondary messenger cAMP (cyclic adenosine 
monophosphate) and largely taken up by the pre-synaptic membrane after release 
from the adrenoreceptors.(134) This latter process is in the order of a few seconds. 
The two systems act differently but synergistically to stabilise the circulation. The 
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relative differences in the delay of release-metabolism/uptake are responsible for a 
subtle competition in the control of heart rate whose by-product is variability.  
 
2.7.7  Humeral control of the circulation 
The finding that aqueous extracts from the adrenal glands could induce increases in 
blood pressure was noted as far back as 1895 by Oliver and Schafer.(145) Indeed, 
adrenaline was the first chemically identified hormone.(146) Dopamine and 
noradrenaline were isolated and synthetised later.(147) All three are chemically 
characterised as catecholamines due to the presence of a catechol nucleus, see figures 
2-12 and 2-13. 
 
Catecholamines are all derived from the amino acid tyrosine which contains a 
catechol nucleus (a benzene ring with two hydrolysed groups [1,2-
dihydroxybenzene]) with an ethyl side-chain to which is attached a terminal amine 
(Figure 2-12). Tyrosine is hydroxylyzed to form L-DOPA (L-3,4-
dihydroxyphenylalanine) which is subsequently decarboxylated to dopamine and 
transported into vesicles in the synapses of the sympathetic nervous system where it 
is hydroxylated to form noradrenaline.(148) 
 
Figure 2-12; Molecular structures of tyrosine and L-DOPA. (This image was obtained 
from http://en.wikipedia.org/wiki/Tyrosine and http://en.wikipedia.org/wiki/L_Dopa on 20.07.2012). 
 
.                        Tyrosine                                                       L-DOPA 
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In the adrenal medulla noradrenaline is methylated to form adrenaline for secretion 
into the blood.(147, 148) Only small quantities of noradrenaline are secreted into the 
blood from the adrenal medulla.(147) Dopamine and noradrenaline differ from 
adrenaline in that they are important central nervous system transmitters. 
 
Figure 2-13; Molecular structure of dopamine, noradrenaline and adrenaline. (This 
image was obtained from http://en.wikipedia.org/wiki/Dopamine, http://en.wikipedia.org/wiki/ 
Noradrenaline and http://en.wikipedia.org/wiki/Adrenaline on 20.07.2012). 
 
             Dopamine                      Noradrenaline                           Adrenaline 
            
  
There are three possible outcomes for noradrenaline molecules following secretion. 
They may be actively reabsorbed by synapses for recycling (which is the fate of 50 to 
80%), they may be destroyed or conjugated locally by tissue enzymes such as 
monoamine oxidase and catechol-O-methyl transferase or they may diffuse into the 
interstitial fluid and from there into the blood.(147-149) 
 
The plasma half-life of plasma catecholamines is of the order of 30 seconds to a few 
minutes. Metabolism by monoamine oxidase and catechol-O-methyl transferase 
taking place principally in the liver.(148)  
 
Catecholamines are responsible for the 'fight-or-flight' reaction that is associated with 
an increase in blood pressure, heart rate and blood glucose. The actions of 
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noradrenaline and adrenaline are summarised in Table 2-1. Generally, adrenaline acts 
upon the heart to increase contractile force and heart rate. Adrenaline also has a 
vasoconstrictive influence on most vascular beds, skeletal muscle being the principal 
exception. Noradrenaline has a similar action on the heart but is also vasoconstrictive 
in skeletal muscle. The effect elicited by adrenoreceptors depends on the type and 
concentration in any one tissue. Catecholamines are important humeral and nervous 
mediators in the defence against shock.(150) The actions of noradrenaline and 
adrenaline in particular serve to maintain perfusion pressure to the vital organs 
(heart, brain and kidneys). They do this by increasing peripheral vascular resistance, 
heart rate and cardiac contractile force.(151) 
 
Table 2-1; The actions of noradrenaline and adrenaline on adrenergic receptors.(152) 
 
 
The process of intubation may have a destabilising effect on haemodynamic function 
by interfering with one or more of the controlling processes outlined above. 
 
2.7.8  Catecholamine analysis methodologies  
Several different methodologies have been used for the determination of plasma 
catecholamines. Bioassays measure physiological responses, an example of which is 
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a modification in blood pressure following the injection of adrenal gland extract. 
These assays are associated with a high level of sensitivity but are not specific.(153) 
Colorimetry exploits the capacity of plasma to give a carmine colour when exposed 
to a variety of oxidising agents. This assay not only lacks sensitivity but also 
specificity.(154) Fluorimetry relies on the property of fluorescence of a phenolic 
group when adrenaline or noradrenaline solutions are treated with strong alkali.(155) 
The specificity of this assay is superior to colorimetry with only dopamine 
interfering and only in large amounts.(156) The disadvantage of fluorimetry is the 
instability of the reactants which means that the interval between addition of the 
reactants, completion of the reaction and measurement is critical.(147) 
 
Other possible methodologies for the detection and quantification of catecholamines 
include gas-liquid chromatography.(147) This is because catecholamines are strongly 
polar, non-volatile and relatively insoluble in most solvents. An alternative is to use a 
radiochemical technique but this is time-consuming and the sensitivity has been 
questioned.(147)  
 
Chromatography, or "colour writing", was developed in the early 1900s by the 
Russian scientist Tsvet to separate plant pigments. Chromatography can either be 
used as a purification method on an industrial scale, as is the case in the extraction of 
petrol from crude oil, or for the analysis of small quantities of molecules in solution. 
The solution to be analysed, or analyte, is dissolved in what is known as the 'mobile 
phase' and is forced at high pressure across a porous 'stationary phase', which is 
usually contained in a column. In analytical chromatography reverse-phase systems, 
ion pairs are formed between appropriate counter ions on the stationary phase and the 
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ionized catecholamines present in the mobile phase.(147) Differentiation of the 
constituents to be analysed occurs due to the relative speed through the column. The 
coefficient of separation is the characteristic that determines the time taken for the 
analytes to leave the column. During of HPLC analysis, noradrenaline is released 
from the stationary phase before adrenaline and before dopamine. A mass 
spectrometer is employed to detect the mass-to-charge-ratio of the mobile phase as it 
leaves the stationary phase.  
 
High-performance liquid chromatography is the principal method for the 
determination of catecholamines since the beginning of the 1990s.(157) High-
performance liquid chromatography makes use of micro-particulate supports for the 
separation and quantification of catecholamines.(147) The use of shorter columns has 
enhanced the concentration of solutes which has improved sensitivity.(147) 
 
Anecdotal evidence from the testing of plasma catecholamines in the Hôpital Robert 
Debré has indicated that they are rarely found either in normal or shocked children 
(personal communication, Dr. Jean-François Benoist). However, there are some 
published studies that have used high-performance liquid chromatography (HPLC) 
for the analysis of plasma catecholamines with success.(158)  
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Chapter Three 
Haemodynamic Instability during Intubation and Anticholinergic Drugs  
____________________________________________________________________ 
 
3.1   Haemodynamic instability during intubation 
 
The modification of any one of the haemodynamic parameters of ejection volume, 
heart rate, cardiac output, blood pressure or blood flow during and as a result of the 
process of intubation is considered to be 'haemodynamic instability'.  
 
3.1.1  Heart rate 
Electrocardiogram monitoring in normal children has demonstrated that spontaneous 
variations in heart rate occur occasionally in infants,(159) young children,(160) and 
boys aged 10-13 years.(161) Regulatory mechanisms promptly re-establish normal 
heart rate and the individual is unaware of the episode.  
 
Prolonged heart rate slowing, bradycardia (from the Greek 'heart slowness', 
brædɪˈkɑrdiə-bradykardía-βραδυκαρδία), is considered to be abnormal. When 
bradycardia persists, several consequences may arise. Firstly, the regulatory 
mechanisms that re-establish heart rate may be inadequate, secondly, a positive 
feedback loop of bradycardia and coronary hypoperfusion may be set-up and finally, 
widespread tissue damage may occur from hypoperfusion. The simultaneous 
presence of pathology may be important in setting the threshold at which these 
events occur. 
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Many arbitrary definitions of bradycardia during intubation have been proposed. 
These are most frequently based on an absolute change in heart rate (11, 13, 162) but 
any 'bradycardic event' (4, 163), a fall below two standard deviations of the mean 
heart rate for age (20), three or more beats at <60min-1(164), <100min-1 (165) or 
percentage reductions in base rate such as 20% (26) or 25% (21) have also been 
proposed. Such non-agreement over any definition what constitutes bradycardia 
during intubation inevitably obscures the true frequency of the event. Carroll et al. 
recently looked at a retrospective cohort of emergency intubations using yet another 
definition of bradycardia (<80min-1 for <2 years or <60min-1 ≥2 years) and found a 
frequency of 10% for emergent intubation compared to 2% for urgent 
intubations.(19) The most obvious reason for this extra-ordinary lack of consensus is 
that none of the above authors have tried to link their particular definition of 
bradycardia to a specific clinical outcome such as changes in other haemodynamic 
parameters or the clinical outcome of death or neurological deficit. Sing et al. 
considered that a fall of 25% from baseline was a ‘haemodynamically significant 
event’ without any justification or the establishment of a relationship with a defined 
clinical outcome.(21) 
 
3.1.2  Drug induced bradycardia 
Leigh et al. made the important observation in 1957 when using the newly 
introduced suxamethonium during routine anaesthesia that severe heart rate slowing 
could occur during the intubation of children.(22) This observation was perhaps the 
first to indicate that the haemodynamic consequences of intubation in children might be 
clinically important. 
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Induction drugs can induce bradycardia due to their capacity to alter autonomic 
balance and/or by direct effects on the heart and vasculature. The heart slowing 
related to the use of suxamethonium has been described as ‘vagomimetic' because it 
is an acetylcholine muscarinic receptor agonist. Second doses have a more prominent 
effect which can be so severe as to provoke asystole.(166, 167) It is probably the 
most important drug-induced bradycardia and is a well known complication of 
suxamethonium.(22, 167) Conversely the use of non-depolarising muscle relaxants, 
such as vecuronium, and rocuronium has been shown to have a tendency to attenuate 
oculocardiac vagal reflex bradycardia.(168)  
 
During routine anaesthetic use of propofol, a 12% frequency of bradycardia has been 
noted in children aged less than four.(169) Propofol slows atrio-ventricular node 
conduction and has been demonstrated to convert supra-ventricular tachycardia to 
sinus rhythm.(170, 171) Fast acting morphine-like sedation agents such as 
sufentanyl, and particularly remifentanil, can also induce bradycardia in both adults 
(172) and children.(173) Thiopental does not have a direct effect on heart rate.(12)  
 
Those induction agents which have no effects on heart rate include ketamine in 
experimental situations (174) and etomidate (175) whose use in the emergency 
department setting has been shown to increase heart rate in children by 10 beats per 
minute although this may be due to an insufficient analgesic effect.(175) 
 
Myocardial contractility may also be reduced by some drugs, such as for thiopental 
and ketamine (5) and propofol.(12, 169) Induction agents can also affect vascular 
tone, vasodilatation being a feature of propofol,(6, 176, 177) thiopentone,(177) 
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remifentanil,(178) sufentanyl (179) and morphine.(180) In contrast etomidate (181) 
and midazolam (182) are not vasodilators.  
 
3.1.3  Reflex bradycardia : hypoxia 
Desaturation of haemoglobin occurs frequently during intubation and is more rapid 
in younger children and during upper respiratory tract infections.(7, 19, 183, 184) 
Hypoxia activates chemoreceptors in the aortic bodies which send afferent signals to 
the vasomotor centre whose response is to lower the heart rate via the Vagus nerve. 
 
3.1.4  Reflex bradycardia : laryngoscopy 
The second source of reflex bradycardia during intubation is the manipulation of the 
laryngopharynx. During laryngoscopy,(8-10) bronchoscopy,(185) insertion of a 
gastric catheter,(186) or during oesophagogastroduodenoscopy(187) mechanical 
stimulation of the laryngopharynx occurs which activates the superior laryngeal nerve. 
The superior laryngeal nerve is an afferent branch of the Vagus nerve. The number of 
attempts at intubation (188) or speed of gastric catheter insertion,(186) which are both 
indirect measures of vigour of laryngopharyngeal stimulation, are associated with 
more frequent bradycardia. 
 
3.1.5  Tolerance and intolerance of bradycardia 
Prior to birth there is dense vagal innervation of the sino-atrial node which is 
associated with poor sympathetic innervation of the ventricles and conduction 
bundles.(113) Periodic uterine contractions may induce placental hypoperfusion 
during labour. To resist, fetuses use reflex bradycardia to maintain blood pressure 
(189) and redistribute flow by selective vasoconstriction.(190, 191) After birth there 
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is a change from parasympathetic dominance to a state of autonomic co-
dominance.(192)  
 
Humans have narrow tolerances for hypoperfusion due to hypoxia and have 
relatively limited access to the adaptive mechanisms possessed by some other 
animals. For instance, the common map turtle can hibernate without oxygen for 
several months and seals can dive aerobically for periods in excess of one hour. Such 
extreme conditions are compensated by adaptive responses that include a reduced 
dependence of neuronal oxidative metabolism (193, 194), tolerance of cardiac 
hypoperfusion,(195, 196) increased oxygen (197, 198) and glycogen (199) storage, 
post bradycardia tachycardia (118) which plays a role in metabolite washout,(196) 
tolerance of metabolic acidosis by increased buffering,(200) tolerance of increased 
lactate levels (201) and cellular hypometabolism.(120)  
 
The important difference between reflex bradycardia and drug-induced bradycardia 
is that during vagal reflex bradycardia the vasomotor centre is activated by efferent 
signals in the Vagus nerve. This maintains pre-load by vasoconstriction thus 
preserving ventricular filling, ejection volume, cardiac output whilst also inducing 
vascular constriction.(115, 202) The net result of reflex bradycardia is a sustaining 
flow whereas drug-induced bradycardia presents a risk to flow.  
 
Specific cases may be at particular risk of bradycardia. For instance, the potential for 
isolated cerebral hypoperfusion to affect neurological function is an important 
clinical outcome to consider. During raised intra-cranial pressure decreases in blood 
pressure are translated directly into decreases in brain perfusion pressure.(203) This 
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is an important risk for secondary ischaemia after cranial trauma.(204) One 
retrospective study of paramedic intubation, as opposed to transport without 
intubation for traumatic brain injury using a historical control group indicated an 
overall increase in mortality and neuromorbidity.(205) Preterm infants experience 
reductions in cerebral blood flow velocities during spontaneous ‘central’ non-reflex 
bradycardia. These have been associated with absent end diastolic flow (206) which 
may be reduced as much as 80% (207) and reductions in cerebral oxygen 
saturation.(186, 208)  
 
3.1.6  Changes in cardiac output and blood pressure 
During routine anaesthesia using halothane (13) and isoflurane (209) maintenance 
and immediately after induction intubation with halothane (11), thiopental and 
suxamethonium (12) and sevofluorane/remifentanil (162) the cardiac index falls. 
Blood pressure also diminishes after halothane induction in children.(210) 
Unfortunately there are no similar studies during critical care intubation in children. 
 
Adult studies of intubation in critical care settings have shown that blood pressure 
falls during intubation and that hypotension is an important associated risk factor the 
for mortality.(3, 16, 17) Marshall et al. studied a group of 10 premature infants 
during intubation noted that blood pressure increased significantly despite a 
significant fall in heart rate.(9) This effect was probably due to the absence of 
sedation but may have been due to the vasoconstriction that accompanies reflex 
bradycardia and which counter-balances reduction in heart rate to maintain, or 
increase, blood pressure. Nevertheless, this finding has been confirmed by a 
randomised trial of propofol versus morphine-atropine-suxamethonium which 
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revealed non-significant increases blood pressure from pre-intubation values for both 
groups.(211) There is a very important differences between the adult and paediatric 
studies. The adult intubations were carried out in a population where blood pressure 
was reduced before intubation whereas the infants were intubated for neonatal 
respiratory distress and had normal blood pressure. 
 
The stimulation of the Vagus nerve is a potential source of haemodynamic instability 
during intubation. The secretion of acetylcholine in the SAN was considered an early 
candidate for pharmacological manipulation. Drugs originally derived from the 
extracts from plants containing anticholinergic properties were used during 
intubation from the 1950's as a means of reducing the occurrence of bradycardia.(22) 
 
3.1.7  Induction and intubation in familial dysautonomia 
Familial dysautonomia (FD) is a hereditary condition of clinically heterogeneous but 
genetically distinct disorders otherwise known as hereditary and sensory autonomic 
neuropathies (HSAN).(212) Familial dysautonomia predominantly affects the 
Ashkenazi Jewish population.(212) The clinical manifestations of FD are due to 
incomplete neuronal development and progressive neuronal degeneration of the 
peripheral and autonomic nervous system.(213) In particular autonomic crises are 
responsible for bradycardia and/or tachycardia as well as vomiting and profuse 
sweating along with other symptoms.(213)  
 
Special consideration is required when considering the choice of induction drugs due 
to the altered effects of drugs that modify the influence of autonomic innervation in 
FD, ketamine being preferred to thiopental.(214) In addition, excessive vomiting or 
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sweating can give rise to metabolic disturbances and hypovolaemia which is a risk 
for anaesthesia particularly in the presence of bradycardia.(213) Despite the potential 
for bradycardia and hypotension the use of the anticholinergic atropine has not been 
recommended for routine anaesthetic induction.(213) 
 
3.2  Anticholinergic drugs 
 
Many plants naturally produce competitive antagonists of acetylcholine. The most 
frequently exploited derivative is atropine, which is a tropane alkaloid. Atropa 
belladonna (derived from the Italian for beautiful lady because if the effects on pupil 
dilatation) is the plant that is most frequently associated with the extraction of 
tropane alkaloids. The common name for atropa belladonna is deadly nightshade. 
Similar plants are to be found in North Africa, Europe and Western Asia. Hyoscine 
was extracted in 1910 followed by atropine which had a quicker absorption and 
faster onset of action.(215)  
 
Figure 3-1; Deadly nightshade berries source of tropane alkaloids (including 
atropine), left, and notice indicating the danger involved in ingesting them, right 
(photos courtesy of Dr. Mark Peters). 
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Atropine antagonises acetylcholine in muscarinic receptors at the post-synaptic 
terminal of parasympathetic nerves. As such it prophylactically prevents vagal 
activation of the sino-atrial node which prevents reflex bradycardia and diminishes 
non-reflex bradycardia. Alternatives to atropine include glycopyrrolate, better known 
for its use in sialorrhoea (excessive drooling), and hyoscine.(216, 217) They are 
equally effective in preventing bradycardia but their side effect profiles differ slightly 
with atropine having a tendency to induce a higher rate of sinus tachycardia.(217-
222) Glycopyyrolate, and particularly hyoscine, have slower onset of action than 
atropine which is of no significance when used as part of anaesthetic pre-medication 
but is clearly not conducive to use in the emergency setting where they have not been 
tested and where no recommendations exist for their use. It is for this reason that this 
thesis confines itself from here on to looking at atropine exclusively. 
 
Figure 3-2; Molecular structures of atropine, hyoscine and glycopyrrolate. (This image 
was obtained from http://en.wikipedia.org/wiki/Atropine, http://en.wikipedia.org/wiki/Hyoscine and 
http://en.wikipedia.org/wiki/Glycopyrrolate on 20.07.2012). 
 
             Atropine                              Hyoscine                             Glycopyrrolate 
            
 
3.2.1  Atropine modifies haemodynamic function during intubation 
Prospective electrocardiogram studies during the intubation of infants(210), small 
(223) and older children and adolescents (26, 164) have shown a general consensus 
that atropine limits, but does not abolish, falls in base line heart rate. Unfortunately, 
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the conclusions of these studies are mitigated by their small sample sizes. In 
intensive care settings a similar trend has been repeated in neonates (224, 225) and 
one retrospective out-of-hospital study.(21) However, this has not been confirmed by 
another retrospective study in an emergency department which showed a 4% rate of 
bradycardia with or without atropine.(20) 
 
Atropine shows a small attenuation of,(210) or no effect on (11, 209) the fall in blood 
pressure during routine anaesthetic induction with inhalation anaesthetics and has no 
effect on the reduction in cardiac index caused by remifentanil.(162) However, 
atropine does increase cardiac index (13) and blood pressure during maintenance of 
anaesthesia with halothane (226) or enflurane.(227)  
 
3.2.2  Side effects of atropine 
The side effects on the heart of atropine at normal doses (10 to 20mcg/kg 
intravenous) in anaesthetic studies are benign in the normal heart and are probably 
limited to sinus tachycardia. Sinus tachycardia nevertheless increases oxygen 
consumption (228) and has been shown to reduce ventricular filling and left 
ventricular end diastolic pressure in normal dogs.(229) This may be of importance in 
critical care situations. 
 
The true cardiac side effects in a normal heart are best elucidated from the reports of 
accidental atropine ingestion where dose levels are high. For instance, during the 
First Gulf War at least 240 children in Israel were poisoned by the injection of adult 
dose “automatic atropine injector” organophosporous nerve agent antidotes but no 
fatalities resulted.(230) Accidental or intentional poisoning of naturally occurring 
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anticholinergic molecules occurs regularly and cardiac toxicity beyond sinus 
tachycardia is generally not a feature.(231-235) Similarly, the absence of cardiac 
toxicity in three children who received more than a thousand times the normal dose 
illustrates just how safe atropine can be in a normal heart.(236) Both hyoscine and 
glycopyrrolate induce similar or less tachycardia than atropine.(217, 220, 222)  
 
In an abnormal heart there is one case report which describes a nine year old girl who 
had spontaneously occurring bigeminism that converted to ventricular tachycardia 
after administration of atropine (237). The conversion from atropine-induced sinus 
tachycardia to ventricular tachycardia has not been proven in children or adults. 
 
Non-cardiac, or ‘peripheral’, side effects in normal children include dilated pupils and 
dry hands and mouth (238) and pro-hyperthermia (239) are well documented. There 
exists at least one report of fatal atropine poisoning which was probably related to 
fever.(240) Other side effects include the inhibition of micturition (233, 241), the 
relaxation of the oesophageal sphincter (242, 243), a reduction in gastric and colonic 
motility.(244) 
 
‘Central anticholinergic syndrome’ occurs more frequently in adults with lethargy or 
excitatory behaviour, hallucinations and coma.(236) When central effects are 
encountered in children, hyoscine is classically sedative whereas atropine is 
excitatory.(217) Stimulation of the Vagus nerve is generally anti-convulsant (245) and 
atropine possesses pro-convulsant activity.(246) An exception is when the seizures are 
initiated by hypoxia from breath-holding attacks, in which case atropine is reduces the 
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frequency of seizures.(247) Glycopyyrolate theoretically has little or no CNS activity 
as it is a quaternary compound and so penetrates the blood-brain barrier poorly.  
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PART TWO 
RESULTS 
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Chapter Four 
An International Delphi Survey of Atropine  
for Critical Care Intubation by 61 Paediatric Intensivists 
_____________________________________________________________ 
 
4.1  Introduction 
 
Atropine has been recommended to be used as pre-medication for anaesthesia from 
as early as the 1950s to attenuate vagally-mediated or drug-induced bradycardia 
during induction and laryngoscopy (22, 164). Later studies showed the advantage of 
atropine in maintaining cardiac output during halothane induction (11). The 
subsequent transition to less bradycardia-inducing anaesthetic inhalation agents and 
non-depolarising muscle relaxants (168) led to the rejection of the routine use of 
atropine (27).  
 
In contrast, several recent reviews have recommended that neonates (29, 30, 47) and 
children under five years (33) should receive atropine prior to critical care intubation 
and the American College of Critical Care Medicine has specifically recommended 
its use for intubation in septic shock in neonates and children (34). The above 
recommendations are based on the opinions of a small number of authors, with the 
exception of that for septic shock, and have appeared without there being any 
recommended clinical outcome or clinical trials of the efficacy or side effects of 
atropine in the paediatric intensive care population (248). Currently, the use of pre-
intubation atropine is an increasing trend in neonatology as is illustrated by the one 
recent survey which noted that approximately half of all UK tertiary neonatal units 
use atropine routinely (32). 
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Qualitative research methods, such as the Delphi method, are tools for obtaining 
consensus where scientific evidence is inconclusive or contradictory, as is the case 
for critical care pre-medication with atropine. The Delphi seeks to establish a 
quantitative assessment of the level of agreement with a statement amongst a group 
of experts by a process of ‘Rounds’ of structured questioning regarding a pre-
determined statement combined with a system of anonymous, iterative feedback. 
This feedback enables the participants to modify their opinion with respect to that of 
the group whilst ensuring that no one participant can dominate the final outcome 
(249). An advantage of the Delphi Method is that the opinions of a large number of 
individuals in diverse locations with differing experience and backgrounds can 
contribute towards enhanced decision making. A disadvantage is that it does not 
provide quantitative data and so cannot replace the need for clinical trials (250). 
 
Our objective was to use a Delphi approach to determine the qualitative influences 
on atropine use during critical care intubation by a group of highly experienced and 
relatively inexperienced Paediatric Intensivists geographically diverse locations. We 
modified the Delphi to examine atropine prescribing practices to determine whether 
it was possible to establish recommendations for the use of atropine by means of 
stratification according to frequency of atropine prescription. 
 
4.2  Methods 
 
4.2.1  Recruitment of the Expert Panel 
An expert panel of three Paediatric Intensivists and a Clinical Epidemiologist was 
created which examined clinical indicators regarding the influences on atropine 
prescription, clinical outcome and the influence of atropine on clinical outcomes. 
74 
 
They proposed nine indicators that were formatted into statements contained in the 
‘Round 1 questionnaire’ using a Likert-type scale. Independent English and French 
reverse translations were used to verify accuracy the questionnaire and all other 
written material. The members of the expert panel were thereafter excluded from 
participation in the study (Figure 4-1).  
 
Figure 4-1; Process of the Delphi survey. The formation of the questionnaire on the 
influences on atropine prescription was followed by two rounds of questions and 
structured feedback with a final rating process and stratification for analysis. 
 
     
4.2.2  Recruitment of the Study Population 
An international group of Paediatric Intensivists, or ‘User Group’, was brought 
together by five Intensivists (Peter Jones, Stéphane Dauger, Niranjan Kissoon, Joe 
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Median <7, with agreement  <60%  
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Round 1 questionnaire 
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use 
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Influences on atropine use 
and new questions 
 
67 Intensivists 
61 Intensivists – User Group 
3 Intensivists,  
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19 Intensivists – Frequent Users 
18 Intensivists – Intermediate Users 
24 Intensivists – Infrequent Users 
 
Round 2 questionnaire 
Influences on atropine use 
 
Final rating process 
Median >7, with agreement >75% 
 
Stratification according to use,  
2/3-always, 1/3-2/3, 0-1/3,  
Quantitative and qualitative feedback  
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Carcillo, and Mark Peters) who then answered the questionnaires between March 
2010 and April 2011. The aim was to include a broad range of age and experience, as 
has been previously recommended (248, 249). An absolute inclusion criterion was 
the prerequisite that each Paediatric Intensivist should have two or more years 
experience in Paediatric Intensive Care and/or Paediatric Intensive Care Transport. 
Importantly, no information was collected regarding prescribing practices for 
atropine prior to recruitment. Agreement to participate in the survey was given by all 
the Paediatric Intensivists when they replied to the Round 1 questionnaire which 
included a letter explaining the functioning of the Delphi methodology. No financial 
incentive was offered. 
 
The Paediatric Intensivists were contacted personally or by email and replied to 
questionnaires principally by email although sometimes by fax. English translations 
were used by all the UK, USA and Brazilian Paediatric Intensivists and French 
translations by the French, Swiss and Dutch participants. The Canadian Paediatric 
Intensivists used either English or French translations according to their preference. 
The opinions of the Paediatric Intensivists regarding influences on the prescription of 
atropine were rated according to their level of agreement, or non-agreement the 
indicators chosen in by the Expert Panel. The Likert Scale rated indicators whereby 
‘1’ indicated strong disagreement and ‘9’ strong agreement. In addition, the 
Paediatric Intensivists were encouraged to provide written comments. Non-
responders were motivated to participate through email contacts, in person or by 
phone by the principal author or the co-author who had recruited them.  
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4.2.3  Process of the study 
An initial rating process rated respondents’ answers according to the quantitative 
level of agreement with the statement at the end of Round 1 (median score) and 
agreement with each other (percentage of respondents agreeing with a median of 7-
9). Three categories of agreement were possible; 1-3 where there was a consensus of 
non-agreement, 4-6 where there was no consensus and 7-9 where there was a 
consensus of agreement. Round 1 questionnaires rated above the cut-off with a 
median score of 7-9 and a consensus of > 60% agreement could be developed into 
new statements to examine other influences on atropine prescription. The comments 
obtained from the User Group were developed into new Round 1 statements. Those 
Round 1 statements which were rated below the cut-off entered directly into Round 2 
(Figure 4-1).  
 
The Round 2 questionnaire included quantitative feedback in the form of the 
individual’s previous response to the Round 1 questionnaire and the median and 
distribution of the User Group. Qualitative feedback was provided with an anonymised 
résumé of the longhand comments. The purpose of the feedback contained in the 
Round 2 questionnaire was two-fold; to enable the Paediatric Intensivist to confirm 
their previous response and permit them to change their responses with regard to the 
responses of the other Paediatric Intensivists. A group conversation between the 
Intensivists was not facilitated, as is sometimes a feature of the Delphi technique, 
because of the differing time zones which would inevitably been biased by the views 
of those most freely able to participate.[13] At the end of Phase II a final rating 
process was used to select indicator/s according to a median score of >7 with a 
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consensus of >75%, as previously used by Shield et al. (251). Those statements with 
a median <3 and a consensus of >75% were considered to have obtained a negative 
consensus. During Round 2 each Paediatric Intensivist was asked to confirm their 
estimated frequency of atropine use. 
 
The User Group was stratified according to the declared estimated frequency of use 
of atropine in the following three Stratified Groups; ‘Frequent Users’ (2/3 to all the 
time), ‘Intermediate Users’ (1/3 to 2/3 of the time) and ‘Infrequent Users’ (0 to1/3 of 
the time). For the purposes of analysis, the Frequent Users group was chosen as the 
reference against which the two other groups’ answers were compared.  
 
4.2.4  Statistical analysis 
Continuous variables are expressed as a mean (standard deviation) or median [inter-
quartile range] according to their distribution and quantitative variables are expressed 
as a percentage (%). A Wilcoxon test was used to compare the median score of the 
User Group answers and a Chi2 test to compare qualitative variables using SAS 9.2 
software (Cary, North Carolina, USA). 
 
4.3  Results 
 
4.3.1  Study population 
Seventy-five Paediatric Intensivists were approached to participate in the User Group 
of whom 68 completed the Round 1 questionnaire. One was excluded for having 
been inadvertently included with less than two years experience and 91% (61/67) 
replied to the Round 2 questionnaire (Figure 4-1). Overall, only three Intensivists 
(5%) participated with less than five years experience and the distribution of 
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experience was similar between the three prescribing groups (Table 4-1). The 
distribution of the 61 according to country is described in descending order; France 
(34), USA (9), UK (8), Canada (6), Brazil (2), and Switzerland (2).  
 
Table 4-1; Characteristics of the 61 Paediatric Intensivists who completed the Round 
2 questionnaire. The Frequent Users are used as the reference for comparison of the 
groups of Intermediate and Infrequent Users. ‘Continental Europe’ countries include 
France and Switzerland and the ‘Americas and UK’ countries include UK, USA, 
Brazil and Canada 
 
 
4.3.2  Stratification of the Study Population 
Forty nine percent (30/61) of the User Group estimated they used atropine for less 
than half of intubations. Nineteen (31%) were Frequent Users of atropine (2/3 to all 
the time), 18 (30%) were Intermediate Users (1/3 and 2/3 of the time) and 24 (39%) 
were Infrequent Users (1/3 to never). There were no significant differences between 
the three Stratified Groups as regards gender, geographical location (divided into two 
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groups of countries; Continental Europe or the Americas and UK), age or number of 
years experience (Table 4-1).  
 
4.3.3  Identification of Influences on Atropine Prescription 
After Round 1, five indicators met the previously determined criteria whereby they 
could be expanded for development in to new statements, these concerned whether it 
is the personal decision to prescribe atropine, the age of the patient, the drugs used 
for induction, the pathology (Q2, 5, 7, 8, Table 4-2) and the influence of atropine on 
bradycardia (Q9, Table 4-3). The influence of a temperature >38.5°C achieved a 
consensus of non-agreement after Round 1 (median 1, 92% agreement, Q6, Table 4-
2). 
 
After Round 2, only the statement regarding whether it is the personal decision to use 
atropine achieved consensus with a median of 7 with 62% agreement in Round 1 
compared to median 8 with 81% agreement in Round 2 (Q2, Table 4-2). The 
indicators of age, induction drug and pathology all retained a median of 7 during 
Round 2 and slightly increased their levels of agreement; 60 to 64% for age, 61 to 
67% for induction drug and 60 to 61% for pathology, none of them achieving final 
consensus (Q5, 7, 8, Table 4-2).  
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Table 4-2; Results of the Round 2 statements relating to the influences on atropine 
prescription. The User Group is divided according to the frequency of atropine 
prescription into the Stratified Groups of Frequent, Intermediate and Infrequent 
Users. The Intermediate and Infrequent Users are compared against the reference of 
the Frequent Users. 
 
* - p<0.05  
§ - If there was no unit policy then the Paediatric Intensivists were required to answer ‘1’. 
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Figure 4-2; Results of the Round 2 questionnaire regarding age and induction drugs.  
The bars represent the percentage of responses in the range of 7 to 9 (meaning that 
the respondents agreed or agreed strongly with the use of atropine in this scenario). 
The User Group is divided according to the frequency of atropine prescription into 
the Stratified Groups of Frequent, Intermediate and Infrequent Users. The 
Intermediate and Infrequent Users are compared against the reference of the Frequent 
Users. 
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The influence of age achieved a Round 2 median score of 7 with a 64% agreement 
(Q5, Table 4-2). When the statement was narrowed as to whether the practice of the 
Paediatric Intensivists was to use atropine for children aged less than six months the 
answer achieved the same median score with a 70% agreement (Figure 4-2). The 
prescribing practices for induction drugs and pathologies are illustrated in Figures 4-
2 and 4-3. 
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Figure 4-3; Results of the Round 2 questionnaire regarding age and induction drugs.  
The bars represent the percentage of responses in the range of 7 to 9 (meaning that 
the respondents agreed or agreed strongly with the use of atropine in this scenario). 
The User Group is divided according to the frequency of atropine prescription into 
the Stratified Groups of Frequent, Intermediate and Infrequent Users. The 
Intermediate and Infrequent Users are compared against the reference of the Frequent 
Users. 
 
 
 
 
 
 
 
 
 
4.3.4  Effect of Atropine on Clinical Outcomes 
The risk of death during intubation achieved consensus when it was first put in 
Round 1, median 8 with 80% agreement compared to median 8 with 82% in Round 2 
although very surprisingly not that for hypotension which had a median 8 with 72% 
agreement versus Round 2 median 8 with 74% agreement (Q10, 12, Table 4-3). 
There was no consensus that atropine reduces the risk of death (median 4 with 41% 
agreement) or hypotension at the end of Round 2 (median 3 with 52% agreement) 
(Q11, 13, Table 4-3). 
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Table 4-3; Results of the Round 2 questionnaire relating to the potential clinical 
outcomes of intubation and influences on atropine prescription on clinical outcomes. 
The User Group is divided according to the frequency of atropine prescription into 
the Stratified Groups of Frequent, Intermediate and Infrequent Users. The 
Intermediate and Infrequent Users are compared against the reference of the Frequent 
Users. 
 
* p<0.05 
 
4.4  Discussion 
 
Our study revealed a clear consensus for three indicators. The Paediatric Intensivists 
agreed that it is their personal decision whether to use atropine (Q2, Table 4-2), that 
there is a risk of death during critical care intubation (Q12, Table 4-3) and there is a 
consensus that fever should not influence the decision to use atropine (Q6, Table 4-
2). Seventy-four percent of the Intensivists agreed that children are at risk of 
haemodynamic disturbance (Q10, Table 4-3). Importantly, there was no consensus 
amongst the User Group as a whole, or in any of the Stratified Groups, that atropine 
84 
 
prevents either bradycardia (Q9, Table 4-3) or reduces the risk of hypotension (Q11, 
Table 4-3) or death (Q13, Table 4-3). 
 
4.4.1  Bias in the Study Population 
A recent survey of the Delphi method noted that only 13% of published articles 
included participants from more than one country.(252) Despite having recruited a 
relatively large number of Paediatric Intensivists from six countries there was an 
over-representation of French Intensivists. This was due to the ease of recruitment of 
this population and potentially limits the general application of the results. We 
achieved an even distribution of age and experience by group of country for the three 
Stratified Groups and additionally managed to sustain a high level of participation 
(91%) which is somewhat above average.(248) We deliberately modified the 
technique from that using only the very experienced to include the views of a few 
relatively junior Intensivists with less than five years PICU experience who have a 
high presence at the bedside.  
 
4.4.2  The Delphi Methodology 
Quantitative methodologies have the advantage of being able to provide information 
regarding potential differences when one therapy is employed rather than another. 
One of their disadvantages is that their conclusions are drawn from populations that 
may be heterogeneous. Subsequent meta-analyses can be used to enhance their 
impact. The difference with a qualitative methodology is that the non-trivial 
importance of years of individual practice, local teaching, discussion, non-scientific 
bedside testing as well as opinion of scientific literature can be assigned a 
quantitative value.(249) The Delphi methodology is well established but, like other 
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quantitative methodologies, may fail to give clear results either because of the 
structure of the questionnaire or anomalies in the selection of the participants or 
because consensus does not genuinely exist.(250)  
 
It is only possible to speculate as to why so little agreement was forthcoming from 
our results, particularly with regard to the use of atropine with specific pathologies or 
drugs. Perhaps there is a critical threshold of literature required for a body of opinion 
to be formed and this is not the case for our subject. The overall deficiency in 
convergence of opinion may be related to intransigently held views of Intensivists as 
a population, as opposed to other specialties, although this should not be taken as a 
comment on the general applicability of the Delphi methodology in ICU.  
 
The most important bias in the survey is undoubtedly the relationship between 
influence on prescribing and prescribing itself. Both are subjective judgements and 
there is no way of separating their influence on each other. There are several reasons 
why we did not to achieve consensus after Round 2 for more of the indicators. 
Firstly, and most importantly, whilst the inclusion of heterogeneous opinions is of 
benefit in generating validity of the results in our survey the Infrequent Users 
responded almost universally with low scores to all statements.(248, 249) This is 
ironically both a strength and a weakness as it reduced the possibility of obtaining 
consensus. The second reason is that there was very little drift towards consensus 
between the two rounds. On the other hand, that the Paediatric Intensivists did not 
change their responses between Rounds 1 and 2 is proof of the ‘stability’ of their 
opinions. A third reason is linked to the methodology, whereby the statements 
regarding the ‘influences’ of, for example induction drugs on atropine prescription, 
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can be interpreted positively but when the statement is rephrased to determine 
associations between atropine prescription and, for example ketamine, some 
Paediatric Intensivists may be positively influenced to prescribe atropine with 
ketamine whereas others may be negatively influenced.  
 
The most sensitive methodological issue with the Delphi is  what is the correct level 
of consensus should be.(248) The level of consensus is chosen a priori by the 
Investigators and may vary according to study methodologies with inevitable 
consequences for the conclusions of the study. There is currently there is no 
quantitative evidence of what should constitute a general level of agreement (218).  
Our a priori use of the 60% agreement cut off during the initial rating process meant 
that the uniform agreement of the Frequent Users and the Intermediate Users was just 
able to assure the development of an indicator by virtue of their relative proportion in 
the study population (37/61, 60%). In practice, however, the selection of an indicator 
required a high level of agreement among the Frequent and Intermediate Users with 
the participation of at least some of the Infrequent Users. The use of a cut off of 75% 
for the final rating process meant that any final consensus needed the substantial 
participation of all three Stratified Groups including the Infrequent Users. 
 
4.4.3  Influences on Atropine Prescription 
It is not unexpected that the age of the child influences the administration of atropine 
even if there was no over-all consensus achieved (Figure 4-2 and Q5, Table 4-2). In 
the early months after birth there is a predominant parasympathetic autonomic 
activity due to dense innervation of the sino-atrial node associated with poor 
innervation of the ventricles and conduction bundles (113) which increases the 
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likelihood of vagally mediated reflex bradycardia during intubation.(4) Overall, the 
User Group poorly complied with the 2002 PALS guidelines that all children <1 year 
and children 1-5 years receiving suxamethonium should also receive atropine (Figure 
4-2).(253) Recent guidelines do not give specific recommendations for drugs for 
rapid sequence induction. 
 
The one consensus of non-agreement that came out of the survey concerns the 
influence of fever (Q6, Table 4-2). The pro-hyperthermic activity of atropine is due 
to its ability to diminish sweating and this is a well known complication in the tropics 
where high ambient temperatures and humidity can raise body temperature during 
anaesthesia.(239) This is unlikely to be a problem where ambient temperatures are 
more moderate and so it is unsurprising that the Intensivists' did not see this as a 
contra-indication to prescription.  
 
The only pathology for which atropine has been specifically recommended is septic 
shock which failed to achieve a 75% consensus among the practice of any of the 
three groups of prescribers (Figure 4-2).(34) Indeed, a consensus was not achieved 
for any of the other pre-existing pathologies or induction drugs that were mentioned 
by the Paediatric Intensivists in Round 1 (Figures 4-2 and 4-3). Suxamethonium 
remains one area of practice where anaesthetists use atropine routinely, at least for 
repeat doses (28) and several published articles clearly indicate the risk severe 
‘vagomimetic’ bradycardia and/or cardiac arrest due to suxamethonium.(22, 167) In 
contrast, non-depolarising muscle relaxants have been associated with an attenuation 
of vagal bradycardia so the use of atropine is probably not indicated.(168) Although 
the use of ketamine has been described during anaesthetic premedication (254) and 
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Emergency Department sedation (255) the methodology of these studies does not 
enable a decision to be made as to the value of combining ketamine with atropine.  
 
The Intermediate Users could perhaps be better described as the ‘Discerning Users’ 
because they attained 78% agreement (Q3, Table 4-2) regarding whether 
‘recommendations from the literature’ influence their decision to use atropine, much 
higher than the Frequent (37%) and Infrequent Users (36%). They esteem that the 
age (78%), pathology (72%) and use of induction drugs (83%) influence their 
prescribing habits, again more often than the Frequent and Infrequent Users. When 
they were questioned regarding their practices they tended to agree with one or other 
of the groups (Figures 4-2 and 4-3). As such, this group and potentially is the best 
guide as regards practice. 
 
4.4.4.  Effect of Atropine on Clinical Outcomes 
The outcome measures for intubation in paediatric critical care (19, 20) or routine 
anaesthetic (223) intubation have classically been regarded as change in heart rate 
because of the high frequency of vagal bradycardia. As such it is perhaps surprising 
that none of the Stratified Groups achieved a consensus after Round 2 that atropine 
prevents bradycardia (Q9, Table 43). One retrospective study in a paediatric 
population has noted a 4% incidence with and without atropine (20) although 
neonatal studies have been more clear in demonstrating the preventative effect of 
atropine on bradycardia during critical care intubation.(224) No suggestions were 
made as to the preferred treatment for bradycardias encountered during intubation. This 
is a limitation of the Delphi methodology whereby new statements are dependent on 
free comments arising from previous rounds. 
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In contrast, the outcomes of studies in adults have focussed on the risk of death or 
hypotension.(3, 16) Clear consensus was achieved by all three Stratified Groups that 
there is a risk of death and consensus was nearly achieved that there is a risk of 
hypotension during critical care intubation (Q10, 12, Table 4-3). However, none of 
the three Stratified Groups considered that atropine had an effect on either of these 
two outcomes, not even the Frequent Users, which is perhaps our most important 
finding (Q11, 13, Table 4-3).  
 
4.5  Conclusion 
 
In conclusion, despite our demonstration of consensus with regards to some 
indicators, our survey exposes that the widespread variation in atropine prescription 
is dependent on personal opinion rather than scientific literature. The Delphi was 
unable to distinguish clear areas of consensus for prescribing atropine in combination 
with induction drugs and in certain disease states. In addition, the methodology 
employed diminished the capacity to achieve positive consensus because the 
Infrequent Users responded regularly with low scores to all statements. The 
Intermediate Users are perhaps the most discerning users who generally prescribe 
atropine for children aged less than 6 months and when using suxamethonium, as did 
the Frequent Users. Whereas the Intermediate Users did not prescribe atropine when 
using ketamine or rocuronium and when intubating older children or those with a full 
stomach, as did the Infrequent Users. Importantly, no consensus was achieved by any 
of the Stratified Groups regarding the potential benefit of using atropine in reducing 
the risk of hypotension or death.  
90 
 
Chapter Five 
A New Definition of Change in Heart Rate during  
Critical Care Intubation by Estimating 'Lost Heart Beats'  
_____________________________________________________________ 
 
5.1  Introduction 
 
Bradycardia is the most frequently reported parameter reflecting haemodynamic 
disturbance during paediatric critical care intubation (CCI).(19, 20, 224, 225) As 
reviewed above, bradycardia occurs by two mechanisms. Firstly hypoxia in the aortic 
bodies(7) and/or mechanical stimulation (10) of the laryngopharynx activate the 
Vagus nerve which reflexly slows the heart due to secretion of acetylcholine in the 
sino-atrial node. Secondly, some induction drugs, such as propofol,(169) fast-acting 
morphine compounds(173) and suxamethonium (22) can slow the heart either by 
direct action on the myocardium or through stimulation of the sino-atrial node. 
Atropine, reduces activation of the sino-atrial node by antagonising the binding of 
acetylcholine on the post-synaptic receptor. This attenuates the reduction in heart rate 
during both routine anaesthetic intubations(22) and those undertaken in the context 
of critical illness.(30)  
 
When defining heart rate a series of measurements, or point estimates, is made from 
which a mean value can be calculated. Centiles can be estimated using the variation, 
or dispersion, from the mean and in children these are often accompanied by an age-
adjusted mean.(256) The 95th centile is frequently used to define the limit of 'normal' 
and 'abnormal'. In the period preceding CCI, age-adjusted normal values are not 
appropriate to define what a normal heart rate is. This because the presence of critical 
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illness often with associated systemic inflammation and fever(257), means that 
demand for metabolites is high so tachycardia is typically present.  
 
Anaesthetic studies commonly describe the change in heart rate from baseline as a 
measure of cardiovascular impact of intubation.(11, 12, 162, 225) Critical care 
studies of intubation have generally used threshold values below which the heart rate 
is considered to be abnormal. In several studies these have been related to normal 
range for age(19) and include <60beats/min(19, 225), <80beats/min(19) or 
<100beats/min.(225) Percentage changes from baseline heart rates have also been 
employed.(21, 209, 210, 223, 258) One study simply used a subjective description of 
‘clinical significant bradycardia”, which may be specific but is unlikely to be very 
sensitive.(4)  
 
Our objective was to describe the distribution of in pre-intubation heart rate in the 
presence of paediatric critical illness in a prospective, observational study. We then 
aimed to establish a lower 95% confidence interval (95%CI) of heart rate that could 
be used as a reference. With these we propose a new approach to characterising CCI 
change in heart rate by calculating the number of 'lost heart beats'. Finally we test 
this approach by describing the impact of atropine pre-medication on numbers of lost 
heart beats during CCI. 
  
5.2  Methods 
 
5.2.1  Common clinical study methodology for chapters 5, 6 and 7 
Chapters 5, 6 and 7 draw data from a prospective, observational clinical study that 
was conducted at the Hôpital Robert Debré. The study was approved by the Comité 
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d'Ethique et d'Evaluation en Recherche Biomédicale of the Groupe Hospitalo-
Universitaire-Paris Nord.  
 
All children undergoing intubation, who were not in asystole and were aged less than 
eight years, were eligible for inclusion. ECG recordings were made in the Paediatric 
Intensive Care Unit (PICU) and by the Paediatric/Neonatal Intensive Care Transport 
Service (ICT) of the l'Hôpital Robert Debré, Paris, France, between September 2007 
and September 2009. A cut-off of eight years above which children were not 
included was used as the hospital protocol was not to administer atropine routinely 
over that age. The prescription of atropine, and other induction drugs, was at the 
discretion of the attending Intensivist. The hospital dose protocols were as follows; 
atropine was 20µg/kg
-1
, etomidate 0.4mg/kg, propofol 2-4mg/kg, ketamine 1-
2mg/kg, thiopental 5mg/kg, morphine 0.1mg/kg, midazolam 0.1mg/kg, sufentanyl 
0.2mcg/kg, suxamethonium 2mg/kg less than 18 months and 1mg/kg more than 18 
months and vecuronium 0.1mg/kg. 
 
The following data were prospectively recorded: age, sex, pathology (neonatal 
respiratory distress [NRD], non-neonatal respiratory distress [non-NRD], cardiac, 
neurological, ear nose and throat [ENT], sepsis and 'other'), principal sedation drug, 
adrenaline use and atropine administration. 
  
Those who received atropine were considered as the ‘atropine' group and those who 
did not were considered as the ‘non-atropine’ group. Children who received atropine 
after the start of the intubation were included in the non-atropine group on the basis 
of the intention-not-to-treat.  The number of attempts at intubation was recorded on 
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the ECG by the Intensivist. Intermittent SpO2 values were printed on the ECGs by 
the monitoring equipment. 
 
During the 24 month recruitment period 414 intubations were performed in the PICU 
and by the ICT Team. Of these, ECG data were collected during 354 intubations. The 
three chapters describing change in heart rate during the first intubation (Chapter 5), 
the incidence of arrhythmia in first and further intubations (Chapter 6) and finally the 
association between atropine use and mortality during first intubations (Chapter 7) all 
drew data exclusively from this clinical study. Due to the requirements for the 
separate objectives in each chapter the number of intubations included in the analysis 
for each chapter varies.  
 
5.2.2  Process of the study  
Prior to intubation, a one-minute baseline ECG strip (25mm/s) was recorded. Two 
paediatric intensivists independently estimated the lowest and highest heart rate from 
the longest and shortest two R-R intervals. The lowest heart rate was subtracted from 
the highest heart rate, which gave a value for the variation in baseline heart rate. The 
standard deviation of these variations in baseline heart rate was calculated, divided 
by two (as above and below the mean) and multiplied by 1.96 to give a 95% 
confidence interval (C). The baseline heart rate was calculated from the average of 
the two point estimates.  
 
During intubation, continuous ECG recording started from the moment of insertion of 
the laryngoscope until the endo-tracheal tube had been positioned in the trachea with a 
SpO2 of >95% or connection to a ventilator. Continuous heart rates during intubation 
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were determined by the measurement of two consecutive R-R intervals every 
5.5seconds (dt) from the beginning to the end of any episode where the heart rate fell 
below the lower 95%CI. An interval of 5.5seconds was used because there was a 
regular break in the PICU ECG recordings between 7-11seconds. The potential loss 
of beats during any 5.5 second interval was considered to be without clinical 
consequences. So as not to record an infinite number of lost beats, the heart rate any 
children who became asystolic was considered to have returned to normal at the 
moment of the start of asystole. Missing data in the ECG recordings were averaged 
between the previous and next heart rate for no more than one 5.5second interval 
every five periods of 5.5seconds. Where data were missing for two consecutive 
intervals of 5.5 seconds the intubation was excluded. Those ECGs where more than 
10% of data were missing were also excluded.  
 
5.2.3  Algorithm for Calculation of Lost Beats 
The number of lost heart beats was calculated by a two-step algorithm; 
 
When C was subtracted from the mean of the baseline heart rate for any individual, a 
fall in heart rate below this number was defined as 'abnormal' and resulted in beats 
being 'lost'. 
 
The second step involved the estimation of the number of lost beats according to the 
following formula; a total number of readings N (meaning that the total time interval 
measured was T=(N -1) dt seconds) and a series of ECG values ei = e(ti) at each time 
interval i = 1,...N gave the total area below the lower 95% confidence interval. The 
integral represents the number of 'lost heart beats' by,... 
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...where t and T are measured in seconds. A numerical trapezoidal approximation is 
used to calculate this interval. 
 
Finally, the means and medians of the changes in heart rate from baseline and lost 
beats, with and without atropine, were compared. 
 
5.2.4  Statistical analysis 
Qualitative variables are described as numbers and percentages (%) and quantitative 
variables as median [quartiles] or mean (standard deviation) according to their 
Gaussian distribution. Independent t-tests or a Wilcoxon test were used for 
continuous data and Fisher's exact test for categorical data. All statistical tests were 
2-sided and the probability of a type 1 error () was determined at <0.05. All 
statistical tests were carried out using SPSS (version 19). 
 
5.3  Results 
 
5.3.1  Study Population 
A total of 333 first intubations in children were eligible for inclusion, 277 intubations 
were included and 245 available for analysis (74%), see Figure 5-1 for the details for 
non-inclusions and exclusions. Ninety-eight children were included from PICU and 
147 from ICT. Atropine was prescribed for 115 (47%) of intubations. One child died 
during intubation. 
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Figure 5-1; Flow chart of inclusions, non-inclusions and exclusions with the number 
of intubations available for analysis according to atropine use. 
 
 
The children who received atropine were significantly younger and had slower 
baseline heart rates. Children who were intubated for non-NRD and those who were 
intubated with propofol or ketamine received significantly less atropine (Table 5-1). 
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Table 5-1; Population characteristics of the 245 children intubated.  
 
* Signifies a statistically significant difference, p<0.05 
 
5.3.2  Calculation of Lost Beats 
Mean baseline heart rate was 153.3beats/min (128.8-177.8) for all patients. The 
standard deviation of the variation in individual baseline heart rate was 
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14.5beats/min, which when multiplied by 1.96 gave the 95%CI of the variability in 
baseline heart rate (28.4beats/min). The 95%CI was divided by two to account for 
variation above and below the mean (14.2 beats/min). The variation in heart rate was 
not modified by age (results not shown). 
 
There was a close linear relationship between the number of lost beats and the time 
spent below the lower limit of normal (Figure 5-2). The slope of the best fit line is 
approximately 45° which means that for every one second spent below the 95%CI 
one heart beat is lost. 
 
Figure 5-2; Relationship between the time and the number of beats lost during 
intubation. There is a close linear relationship with an r
2
 of 0.93. 
 
 
5.3.3  Comparison of Fall in Heart Rate and Lost Beats 
Several examples of intubations where the fall in heart rate was more than 50 
beats/min are illustrated in Figure 5-3. Similar falls in heart rate could produce very 
different numbers of lost beats; from three-fold to 56 fold (Figure 5-3 A and C). 
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Another example shows intubations with very similar loss of beats but with a two-
fold difference in fall in heart rate (Figure 5-3 B). One child died during intubation 
with septic shock, severe chronic pulmonary hypertension with a lethal chromosomal 
disorder (figure 5-3[D]). 
  
Figure 5-3; Changes in heart rate during several different intubations. These are 
extreme examples where the heart rate fell from baseline by more than 50 beats/min; 
A, shows two intubations with similar fall in heart rate (fall HR) and more than 50 
fold differences in lost beats (lost beats), B, shows two examples where the number 
of lost beats was similar but the fall in heart rate 50% greater, C, shows two 
examples where the fall in heart rate was less but there remained more than a three-
fold difference in lost beats and D, is the one child who died in the study having lost 
503 beats before an asystolic arrest. Inter-bradycardia tachycardia is also apparent in 
B. Note that the scales on the x-axes are different for each graph.  
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Using the administration of atropine and/or adrenaline during the intubation process 
as a marker of haemodynamic instability the lowest heart rate during intubation and 
accumulation of lost beats is compared in Table 5-2. Only six children received 
atropine after the start of intubation of which two also received adrenaline. No 
children received adrenaline without having received atropine. Both the lowest heart 
rate and the accumulation of lost beats were significantly associated with this 
definition of haemodynamic disturbance during intubation. 
 
Table 5-2; The association between change in heart rate or numbers of lost beats and 
the use of atropine and/or adrenaline for bradycardia after the start of intubation. 
 
 
5.3.4  The Association between Atropine use and Losing Beats 
Atropine had a significant influence on change in heart rate as assessed by difference 
from baseline to the lowest heart rate.  In comparison, the number of lost beats was 
not significantly affected by the use of atropine (Table 5-2). 
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Table 5-3; Comparison of change in heart rate from baseline and number of lost 
beats showing the association with atropine use. 
 
*Signifies a statistically significant difference, p<0.05 
 
When the heart rate fell by more than 50 beats/min there was a linear relationship 
between fall in heart rate and lost beats (Figure 5-4) with the median number of lost 
beats being 0[0-1] (n=175 with and without atropine). One intubation, with a fall in 
heart rate of 48 beats/min, registered 35 lost beats. Otherwise, all intubations where 
the fall in heart rate was less than 50beats/min were of less than 25 lost beats. The 
progression of lost beats after a fall in heart rate of more than 50beats/min was 
exponential showing a wide dispersion with a median of 42 lost beats [15-83] 
(n=70). When no atropine was used, 76% (99/130) of intubations involved lost beats 
whereas 19% (22/115) involved lost beats when atropine was used.  
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Figure 5-4; Distribution of the lost beats with and without atropine (n=130 for no-
atropine and n= 115 for with atropine). The r
2
 for no-atropine is 0.41 and 0.85 with 
atropine. Note the similarity between the two best-fit curves (dotted lines) both in 
terms of take off and slope. All children survived intubation except the labelled that 
labelled 'Died'  
 
  
 
5.4  Discussion 
 
The 95% confidence interval around the mean baseline heart rate for an individual is 
plus-or-minus 14.2beats/min. During intubation there was a linear increase in lost 
heart beats until the heart rate had fallen by 50beats/min. Thereafter there was an 
exponential increase in loss of beats with a poor correlation between fall in heart rate 
with numbers of lost beats. Atropine pre-medication before CCI was associated with 
a reduced change in heart rate from baseline and reduced number of lost beats.  
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5.4.1  Possible Sources of Bias 
Several methodologies have been used to determine heart rate; a clinical 
measurement without further description(257), a single pulse oximeter reading,(259) 
apical heart rate measured over 15 seconds multiplied by four,(260) one R-R interval 
on an ECG (261) or during automatic blood pressure measurement.(262) We 
recorded baseline heart rate for one minute and averaged the two extremes of heart 
rate. It is possible that if a longer recording had been made more variation would 
have been registered and this would have increased both the standard deviation and 
therefore the 95%CI. The effect of these changes would have been to reduce the 
numbers of lost beats for any one individual. Case-mix differences also exist in the 
sample population. In this respect the population would have benefited from 
recruitment with prospective randomisation. 
 
5.4.2  Clinical Significance 
Neither the use of absolute changes (11-13, 162) nor the use of percentage changes 
(209, 210, 258) from baseline are indicators of risk of haemodynamic 
decompensation (defined as use of adrenaline, cardiac massage or death) during 
intubation. The application of the lost beat score introduces the concept of what is 
normal and abnormal heart rate and integrates the dimension of time. This may give 
a better estimate of risk but further studies will need to be performed to validate this. 
When the heart rate falls by more than 50beats/min, the possibility of a 50 fold 
difference between the numbers of lost beats for the same fall in heart rate may give 
an indication that loss of beats may be a preferable measure of risk of haemodynamic 
decompensation. (Figure 5-4). This represents the clinical situation where fall in 
heart rate is a frequent event but haemodynamic decompensation is infrequent. This 
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suggests that fall in heart rate is a selective indicator for haemodynamic instability 
whereas loss of beats may be a more specific indicator for haemodynamic 
decompensation. 
The lost beat algorithm defined a 95% confidence interval whereby 95% of children 
prior to intubation would have a heart rate in the range.  Pincus et al.(263, 264) used 
a calculation to quantify regularity in serial data, which they defined as 'appropriate 
entropy' (ApEn). An important difference between our two methodologies is that we 
use only two data points per individual, whereas ApEn requires at least 50 data 
points, and ApEn does not exclude data within a defined set of limits, which 
counting lost beats does. Another difference is that we do not measure regularity, as 
does ApEn, but we define normality and measure heart rate that falls outside our 
definition. 
 
 5.4.3  Algorithms in other Biological Systems 
Biological risk is often described as a degree of exposure over time. For instance, 
underwater divers who experience short dives at deep depths can be of equal risk of 
the decompression sickness as longer dives at shallower depth.(265) And ionizing 
radiation exposure is measured by intensity and as a factor of time.(266) Both of 
these risks are characterised in linear no-threshold models (LNT) whereby any 
increase in exposure equates to an increase in risk. LNT models don't apply for the 
risk of haemodynamic decompensation because of compensatory changes in ejection 
volume and vascular resistance. For instance, heart rate in healthy,(267) premature 
(268) and shocked (269) neonates is poorly correlated with cardiac output whereas it 
is highly correlated with stroke volume and systemic vascular resistance. One article 
has already proposed that the risk of haemodynamic instability during intubation is 
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related not to the presence of bradycardia but the absence of accompanying 
vasoconstriction.(270) Any threshold for haemodynamic decompensation that exists 
for an individual during CCI will be determined by the interaction between 
physiology and pathology. Pre-intubation parameters such as low blood pressure, 
tachycardia and the need for inotropes, have been identified as risks for mortality 
during adult studies (3, 16) and give an indication that the threshold is low. If the loss 
of beats is calculated and displayed in real-time this may also give an indication of 
risk of haemodynamic decompensation. 
 
5.5  Conclusions 
 
A variability of 14.2 beats/min above and below the baseline heart rate (or perhaps 
15 as an aide memoire) is typical of critical illness. Fall in heart rate is a very poor 
indicator of loss of beats and should not be used as a performance indicator of a 
successful intubation, certainly when the fall in heart rate is greater than 50beats/min. 
Atropine was significantly associated with change in heart rate but not loss of beats. 
Monitoring equipment at the bedside could be equipped with an algorithm that would 
calculate numbers of lost beats in real-time during intubation. Further studies are 
needed to validate whether this would be a reliable indicator of risk of 
haemodynamic disturbance. 
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Chapter Six 
The Association of Atropine with Reduced Rhythm and Conduction 
Disturbances during 322 Critical Care Intubations 
_____________________________________________________________ 
 
6.1  Introduction 
 
Paediatric critical care (19, 224) and anaesthetic intubation (223) may result in 
slowing of the heart. The causes of this are two-fold. Firstly, stimulation of afferent 
fibres of the Vagus nerve occurs due to the hypoxia and/or mechanical stimulation of 
the laryngopharynx with terminal efferent fibres secreting acetylcholine in the sino-
atrial node(270). And secondly, the use of various induction drugs such as halothane 
(271), rapidly-acting morphine analogues, sufentanyl and remifentanil (172, 173), 
propofol (163) or suxamethonium (22, 23) also tend to slow heart rate. The overall 
effect may be to expose the circulation to the risk of bradycardia related arrhythmias. 
Certain drugs, such as halothane and may also increase the frequency of 
arrhythmias.(271)  
 
Atropine was proposed in the 1950s to limit bradycardia due to its antagonistic action 
on the post-synaptic acetylcholine receptor.(22) In normal children atropine toxicity 
is benign and is related to changes in pupil size, reduction in glandular secretions 
with cardiac toxicity limited to sinus tachycardia.(230, 232, 270) But in routine 
anaesthesia atropine has been shown facilitate the progression to ventricular 
extrasystoles and unusually ventricular tachycardia (237) and fibrillation.(272) 
Indeed, one study concluded that the incidence of ventricular arrhythmias was so 
high with atropine that its use during routine anaesthesia should be 
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'reconsidered'.(221) By the 1990's the wide-spread use of non-cardiotoxic 
sevoflurane and non-depolarizing muscle relaxants led to the discontinuation of 
atropine for routine anaesthetic induction.(28) 
 
Recently however, atropine has been recommended for the maintenance of 
haemodynamic integrity in intensive care populations by several authors but without 
knowing the frequency or importance of atropine's efficacy in stabilising the 
circulation and potential side-effects.(30, 34) This is in spite of the increased risk 
during critical care intubation of arrhythmias due to the complex amalgam of rapid 
changes in heart rate, electrolyte abnormalities, hypoxia, perfusion abnormalities, 
acidosis and hypercarbia, and the effects of induction drugs.  All of these effects may 
be exaggerated in the presence of myocardial dysfunction or congenital 
abnormalities.  
 
Our objectives were to describe the prevalence of arrhythmia before critical care 
intubation and test the hypothesis that atropine was not associated with a change in 
incidence of new arrhythmias or conduction abnormalities either after its 
administration or during intubation. 
 
6.2  Methods 
 
6.2.1  Study design 
Data for analysis in this chapter are drawn from the common methodology of the 
clinical study that is described in Chapter 5 (5.2.1). 
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6.2.2  Study procedures 
Two Paediatric Intensivists reviewed the ECGs independently. An average was made 
of their readings of the baseline heart rate, two minutes after atropine administration 
and the lowest two R-R complexes during intubation (not necessarily at the time of 
the arrhythmia). All potential episodes of arrhythmia were recorded for review by an 
Electrophysiologist. A random sample of 10% of the ECG recordings that were 
considered to be normal by the two intensivists was also examined by the 
Electrophysiologist to control for false negatives. 
 
Sinus brady/tachycardia was regarded as a normal rhythm. Abnormal rhythms were 
considered to be atrial or ventricular extra-systoles, ectopic rhythm, ventricular 
tachycardia or fibrillation. Abnormalities of conduction were also noted 
 
Patients who were not in sinus rhythm at baseline were excluded from the atropine 
analysis. The remaining cases were divided into the two groups of 'atropine' and 
'non-atropine'. Intubations were classified according to the ‘intention-to-treat’ with 
atropine or not as prophylaxis. Atropine given as rescue treatment for established 
bradycardia was not considered in this classification.   
 
Sub-groups were defined of neonatal (<28 days post-natal age), older children (>28 
days post-natal age) and 'further' intubations (of all ages). Further intubations were 
derived from the patients who were re-intubated during the same or a subsequent 
illness after planned extubation and/or for change of endo-tracheal tube. Further 
intubations were treated as new events so as to restrict bias in the groups of primary 
intubations by not replicating data from the same children. The rationale of dividing 
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the group at 28 days was due to the physiological transition in autonomic innervation 
from predominant parasympathetic to co-dominance that occurs during early extra-
uterine life (113). 
 
6.2.3  Statistical analysis 
Qualitative variables are described as numbers and percentages and quantitative 
variables as median [inter-quartile range] or mean (standard deviation) according to 
their Gaussian distribution. Independent and paired t-tests were used for continuous 
data, a Chi
2
 test for categorical data where there were three or more variables and 
Fisher's exact test where there were two variables. All statistical tests were 2-sided 
and the probability of a type 1 error () was determined at <0.05. Univariate and 
stepwise multivariable logistic regression models were constructed to test the 
association of atropine and other pre-intubation variables on the occurrence of new 
arrhythmias using a maximum of one co-variate per 10 new arrhythmias or 
conduction disturbances. Only variables that were significant p<0.20 in the 
univariate analysis were entered into the multivariable model. Effect estimates were 
calculated for numerical variables and odds ratios (OR) for categorical variables with 
their corresponding 95% confidence intervals (95%CI). All statistical tests were 
carried out using SAS V.9.2 software (SAS, Cary, NC).  
 
6.3  Results 
 
6.3.1  Study Population 
Four hundred and fourteen intubations were eligible for inclusion. Sixty intubations 
were not included, generally due to urgency or high work-load conditions, and 
twenty-seven intubations were subsequently excluded, generally due to poor quality 
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recordings (Figure 6-1). Three hundred and twenty seven intubations (79%) were 
available for analysis. A total of 185 intubations were performed in PICU (115 first 
intubations and 70 further intubations) and 142 by the ICT team (with 140 first 
intubations and two further intubations). The ICT team’s activity was predominantly 
neonatal (118/142 intubations, 83%). Eleven ICT intubations were performed out-of-
hospital. Seventy-two further intubations were performed on 42 children (40 in PICU 
and two by ICT) with a median of 2[2-3] intubations per child who were re-
intubated.  
 
Figure 6-1; Flow-chart of inclusions, non-inclusions and exclusions. The five 
intubations where normal sinus rhythm was not present before intubation were 
excluded from the atropine analysis. Neonates are <28 days, older children >28 days 
and less than 8 years and further intubations are any age below 8 years. 
 
* ICT antenatal positioning refers to the presence of the ICT team prior to high-risk 
deliveries, generally these were extremely premature births. 
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There was no significant difference between the median number of attempts at 
intubation with and without atropine (1[1-2] versus 1[1-2], p=0.46) or the median 
trough SpO2 (74% [49-88] no-atropine versus 75% [50-89] atropine, p=0.95). Data 
were missing for 24 intubations for the attempts at intubation and 10 intubations for 
the SpO2. 
 
6.3.2  Pre-intubation Arrhythmias 
The prevalence of baseline arrhythmia before the start of intubation was 1.5% 
(5/327). These intubations were excluded from the subsequent analysis. One 
intubation had frequent bursts of ventricular tachycardia interspersed by junctional 
rhythm in a patient with leukemic infiltration of the heart. This child died some hours 
after intubation.  Another was intubated for ventricular fibrillation in the context of 
Shigella septicaemia and multiple organ failure and died during intubation. Two 
cases had long-standing left bundle branch block from a cardiac malformations and 
one other an atrial ectopic beat.  
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6.3.3  Atropine Use 
A total of 322 intubations were analysed for the association between atropine and the 
emergence of new arrhythmias and conduction disturbances during intubation. 
Atropine was used in 47% (152/322) intubations and 53% (170/322) were without 
atropine (Figure 6-1). Atropine was used in a similar proportion (p=0.12) of cases in 
each of the three sub-groups (neonatal, >28 days to <8years and further intubations). 
The baseline characteristics of the cases in the sub-groups are presented in Table 6-1 
and 6-2. 
 
6.3.4  Changes in Heart Rate and Rhythm after Atropine before Intubation 
A total of 55 ECGs were identified by the Intensivists as being abnormal of which 48 
were confirmed by the Electrophysiologist as being abnormal. None of the ECGs 
considered to be normal by the Intensivists were considered to be abnormal by the 
Electrophysiologist giving 100% sensitivity and 87% specificity.  
 
After the administration of atropine the mean baseline heart rate of all patients rose 
from 153 beats/min (127-179) to 171 beats/min (148-194) (p<0.001). This was seen 
across all sub-groups.  The mean heart rate after atropine administration before 
intubation was significantly higher than baseline in the neonatal group (p<0.001, 
166beats/min [147-185]), the older children (p<0.001, 176beats/min [146-206]) and 
the further intubations (p=0.003, 177beats/min [157-197]). No arrhythmias were 
detected in the minute of ECG recording following atropine injection but before 
intubation. 
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6.3.5  Atropine and New Arrhythmias 
The mean heart rate fell significantly for all patients when atropine was not used 
(p<0.001). Junctional and atrial ectopic rhythms were significantly more frequent 
when atropine was not used (Table 6-3). Other new arrhythmias and conduction 
disturbances are presented in Table 6-3. Overall, the new arrhythmias are related to 
heart slowing and their frequency was higher for those intubations where atropine 
was not used (p<0.001) (Tables 6-3 and 6-4). Three cases of acute bundle branch 
block and five cases of sinus pause with ventricular escape were noted when atropine 
was not used. No new cases of acute bundle branch block were recorded with 
atropine used.  
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Table 6-4; Univariate and multivariable regression analysis for new episodes of 
arrhythmia and conduction disturbances compared to age, baseline heart rate, sex, 
atropine and sedation drugs for all intubations irrespective of age or further 
intubation. One co-variate was entered into the model per 10 new arrhythmias or 
conduction disturbances. Only variables with p values of p<0.20 in the univariate 
analysis were entered into the multivariable model. 
 
* indicates a statistically significant result, p<0.05 
NS variables that were eliminated during stepwise multivariable regression for 
p>0.05 
 
The multivariable regression model revealed that atropine was associated with a 
significant decrease in new abnormal rhythms and conduction disturbances (Table 6-
4). To test for the interference of the further intubations, a post hoc analysis for only 
the first intubations of neonates and older children which revealed a more important 
association with atropine use in reducing new arrhythmias or conduction 
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disturbances (OR 0.10, 95%CI 0.03-0.35, p<0.001). Similar tendencies were 
observed for the other co-variates (results not presented). 
 
Figure 6-2; Distribution of arrhythmias according to groups of lowest heart rate 
during intubation showing increasing frequency of arrhythmia and conduction 
abnormalities as the heart rates falls.  The mean heart rates for those who did and did 
not receive atropine are shown with standard deviation bars. 
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Figure 6-3; Examples of some arrhythmias and conduction abnormalities recorded 
during intubation. With the exception of chronic bundle branch block in C, all ECGs 
were in normal sinus rhythm before the start of intubation.; A, acute bundle branch 
block, sinus pause followed by ventricular extra-systole; B, infranodal block, Mobitz 
type II; C, chronic bundle branch block with atrial ectopic pacemaker; D, sinus pause 
with ventricular escape rhythm and atrial trigeminism; E, sinus bradycardia followed 
by junctional rhythm; F, sinus pause with ventricular escape rhythm followed by 
asystole; G, sinus pause with junctional extrasystole followed by ventricular escape 
rhythm.  
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6.4  Discussion 
 
Arrhythmias and conduction disturbances were prevalent in 1.5% (5/327) of children 
prior to intubation. No new arrhythmias were documented in the minute of recording 
post-atropine and pre-intubation in the 152 intubations where atropine was 
administered. We disproved our hypothesis and showed that there was a significantly 
higher frequency of abnormal rhythms and conduction abnormalities when atropine 
was not used during intubation (43[25%] without atropine versus 7[4.5%] with 
atropine, OR 0.14, 95%CI 0.06-0.35, p<0.001).  
 
6.4.1  Population Bias 
Several possible sources of bias are present in our study. A disharmony in the case-
mix of the two groups exists with those with higher heart rates and younger children 
receiving more atropine (Table 1). Children in the first few months of life have 
predominant parasympathetic innervation (113) and so have an increased propensity 
to bradycardia when the Vagus nerve is stimulated.(4) Nevertheless, this is not 
confirmed by our results wherein the older children had the lowest mean heart rate 
during intubation (Table 6-1 and 6-2).  
 
Other imbalances between the two groups include the use of propofol which was 
more frequently used in the older children and has been previously associated with 
bradyarrhythmia.(169) Overall the use of muscle relaxants was low. This is due to 
three reasons. Firstly, the relatively high number of neonates (practice in the 
Hospital, and Paris Region, was not to include paralysis during the study years), 
secondly, the relatively frequent use of propofol which gives good intubation 
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conditions without muscle relaxants (273) and finally the PICU practice which has 
traditionally had a high-case load of ENT patients.  
 
The inclusion of a 'further' intubation group increased the frequency of inclusion of 
some children with longer illnesses and it is for this reason that these results are 
presented as a subgroup to avoid introducing bias. The advantage of examining the 
re-intubations is that they represent real-life practice and this is also featured in other 
intubation studies.(19) The fact that our study was not randomised is inevitably a 
limitation in the validity of the results. Randomisation in some circumstances may be 
so difficult that it may result in unbalanced populations which can create bias. 
Obtaining the written consent from both parents would probably have lowered our 
high inclusion rate (79%). 
 
The intubation conditions as regards number of attempts at intubation were similar 
for the groups with and without atropine and these were similar to those previously 
described in neonatal (211, 224, 225) and paediatric studies.(19, 20) An exception is 
the median trough saturation in our group of older children which was lower than in 
two other studies.(19, 20) However, these studies mention that the retrospective 
nature of their methodologies was a cause of possible bias in this respect. 
 
The older children (19/61, 31%) and further intubations (11/41, 27%) had a tendency 
to receive less atropine and experienced proportionately more new arrhythmias than 
the neonates (8/68, 12%). This is at variance with the opinions of McAllister and 
Gnauck (274), when discussing arrhythmia during intubation, who concluded that 
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'infants are at greater risk than older children for bradycardia-induced 
haemodynamic compromise'. 
 
6.4.2  Atropine and the incidence of new Arrhythmias 
The prevalence of pre-existing arrhythmia was low (1.5%). Two of the five 
intubations were undertaken as part of the therapy for the arrhythmia, two were 
related to congenital heart disease and one was inconsequential.  
 
The absence of cardiac toxicity using therapeutic and above-therapeutic doses of 
atropine in a normal heart, beyond sinus tachycardia, has been rarely reported in the 
literature and is evidence of its innocuous nature.(230, 232, 270) Of the 154 
intubations which concerned atropine on our study, we demonstrated that pre-
existing sinus tachycardia progressed only to faster sinus tachycardia and not 
ventricular arrhythmias. Given the relatively high frequency of ventricular 
extrasystoles and other ventricular escape rhythms that have been described in 
anaesthetic studies with atropine and the relative absence of such rhythms in our 
intubations, the most likely conclusion is the interaction of atropine with the 
inhalational anaesthetic agents was responsible.(271) Of the seven intubations which 
were performed with atropine when the child had a previously detected abnormal 
heart, and normal pre-intubation ECG, only one demonstrated sinus pause rhythm 
and ventricular extrasystole during intubation. 
 
The absence of atropine was associated with low absolute heart rate which was 
associated with new arrhythmias (Figure 6-2). Indeed, of the 21 intubations where 
the heart rate fell below 60beats/min as many as 76% exhibited new arrhythmias. 
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The highly statistically significant association of atropine and reduced frequency of 
new arrhythmias was probably due to its inhibition of vagal pressure on the sino-
atrial node which generally maintained pre-intubation heart rates and therefore 
normal rhythmicity (Tables 6-3 and 6-4).  
 
All the new intubation abnormalities observed were related to bradycardia and fall 
into three categories; atrial ectopic rhythms, sino-atrial pause accompanied by 
ventricular escape rhythm and impulse conduction abnormalities (Figure 6-3). 
Ectopic atrial and junctional pacemakers have previously been shown to be relatively 
frequent in paediatric anaesthetic studies.(221, 275, 276) Ventricular filling is little 
compromised by atrial ectopic pacemakers at rest because 70 to 80% of ventricular 
filling is passive(25). This may not be the case for hyper-dynamic circulation during 
shock. Those ectopic atrial contractions that are transmitted through the AV junction 
are generally blocked from inducing ventricular contractions by the relatively long 
refractory period of the Purkinje fibres.(277) But, when the ventricular myocardium 
is deprived of coordinated impulses from the atria, ventricular escape rhythms may 
develop (Figure 6-3). Ectopic ventricular contractions may additionally reduce 
contractile efficiency by the propagation of sub-optimal action potentials between 
ventricular myocytes. This may generate a negative feedback loop of poor cardiac 
output and myocardial ischaemia above and over and above the hypoperfusion of 
severe sinus bradycardia.(278) 
 
6.4.3  Conduction Disturbances 
Acute bundle branch block is an important finding which was noted in three patients 
all of whom were intubated for septic shock. One of the three had a pre-existing 
124 
 
cardiac abnormality (pulmonary hypertension) and died during intubation. Acute 
bundle branch block is a risk for progression to sudden and complete heart block 
which can be fatal.(279) The occurrence of a second degree 2:1 atrioventricular 
block (Mobitz type II) during one re-intubation represents an abrupt failure of 
atrioventricular conduction and is also a potential risk for complete heart block and 
asystole (Figure 6-3).(280) These episodes had self corrected by the end of 
intubation. None of the children involved in these intubations had received atropine. 
 
The relative contributions of induction drugs to the creation of new arrhythmias 
shows that etomidate (multivariate analysis) and ketamine (univariate analysis) have 
a tendency to induce arrhythmias when compared to 'no drugs' and propofol tends to 
be protective (Table 6-4). These results should be interpreted with caution for two 
reasons. Firstly, etomidate and ketamine were used predominantly in septic shock 
and propofol for non-NRD and secondly because the majority of children intubated 
without drugs were neonates (Table 6-2). Sufentanyl and morphine tended to be 
protective whereas midazolam was not which is perhaps due to the superior 
intubation conditions when sedation is used (Table 6-4). 
 
6.5  Conclusions 
 
The prevalence of pre-intubation arrhythmias was low (1.5%). Atropine did not 
provoke any new arrhythmias during the minute of recording after administration 
before intubation. Intubation without atropine was more frequently accompanied by 
bradycardia and arrhythmia that when atropine was used. Five intubations without 
atropine, compared to one with atropine, exhibited bradycardia that involved sinus 
pause with ventricular escape. One of these intubations, without atropine, culminated 
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to the death of the child. The relative safety of intubation with atropine is probably 
superior to that when atropine is not used. A randomised study would enable the 
association observed to be validated. 
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Chapter Seven 
Atropine for Critical Care Intubation in a Cohort of 264 Children  
and Reduced Mortality unrelated to Effects on Bradycardia 
_____________________________________________________________ 
 
7.1  Introduction 
 
Critical care intubation (CCI) of young children in critical care situations represents a 
crucial moment in an episode of critical illness and may be associated with 
cardiorespiratory decompensation. In critically-ill adults the risk of death during CCI 
has been estimated at 1- 3% with pre-existing hypotension greatly increasing this 
risk.(3, 16) In children intubation mortality is probably substantially lower. No 
deaths were observed in either of two retrospective studies of 137 intubations in 103 
children outside the Operating Room (19) and or 143 children in the Emergency 
Department.(20)  
 
Paediatric anaesthetists and intensivists have used slowing of the heart rate in 
children as a measure of haemodynamic stability during CCI for more than 50 years. 
Two distinct mechanisms contribute to falls in heart rate during intubation; the direct 
effects of some induction drugs, and vagally-mediated parasympathetic cholinergic 
inhibition of sino-atrial node activity as a reflex response to hypoxaemia and/or 
laryngeal stimulation.(270) 
 
Atropine was proposed in the 1950s to overcome the anti-cholinergic effects of 
suxamethonium during induction and intubation.(22) Its efficacy in attenuating falls 
in heart rate during anaesthetic intubation in children is proven.(164, 223) Following 
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the introduction of non-depolarising muscle relaxants and less cardio-depressant 
anaesthetics, such as sevoflurane, there has been a decline in atropine use.(28) 
 
Atropine is currently recommended to optimise haemodynamic stability during 
CCI.(30) The 2007 American College of Critical Care Medicine clinical practice 
parameters for hemodynamic support in paediatric septic shock provide a level III 
(expert opinion) recommendation for “Ketamine and atropine pretreatment ...[to] be 
used as a ...induction regimen of choice to promote cardiovascular integrity”.(34) 
The lack of prospective data on the impact of atropine on heart rate and outcome in 
critically ill children prompted this study.  
  
Our objective was to measure the association between atropine use and mortality and 
heart rate in a prospectively-recruited population of children undergoing their first 
critical care intubation. We assumed the null hypothesis that atropine was not 
associated with either outcome. A propensity score was used to adjust for patient 
specific prognostic characteristics that might have influenced atropine prescription. 
 
7.2  Methods 
 
7.2.1  Study design and population 
Data for analysis in this chapter are drawn from the common methodology of the 
clinical study that is described in Chapter 5 (5.2.1). 
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7.2.2  Study procedures 
Children were retrieved intubated and transported to three other PICUs (Kremlin-
Bicêtre, Necker, and Trousseau) and five Neonatal ICUs (Creteil, Institut de 
Puériculture, Montreuil, Port Royal, Robert Debré) in the Paris Region which 
participated in the study.  
 
All children who were undergoing their first non-planned intubation and were not 
asystolic were eligible for inclusion. The PRISM III-24 (281) (Paediatric RISk of 
Mortality) score was recorded. Mortality prior to intensive care discharge was 
recorded. 
 
The study population was divided a priori into two age sub-groups, neonatal (<28 
days post-natal age) and older children (>28 days post-natal age and <8 years), for 
the purposes of analysis. The rationale to divide the group at this age was due to the 
physiological transition in autonomic innervation that occurs during early extra-
uterine life (113) and due to the different distribution of pathologies in the two 
groups. 
 
A one-minute ECG control strip (25mm/s) was recorded prior to the start of 
intubation, two minutes after atropine if administered, and used to calculate the mean 
pre-intubation heart rate by averaging the lowest and highest heart rate.  
 
7.2.3  Propensity score construction 
The propensity score (PS) is a one-dimensional summary of multidimensional 
covariates that is used to make causal inferences in observational studies by dealing 
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with confounding patient-specific prognostic characteristics that could have an effect 
on both treatment assignment and outcome. This allows a statistical balancing of the 
two treatment groups by adjusting for a series of pre-treatment confounding 
variables. The PS for a group of patients is the sum of the probabilities for having 
received a particular treatment according to a specified set of pre-treatment 
covariates that might plausibly have affected treatment assignment.(282, 283) 
 
We constructed a PS for atropine prescription using the pre-prescription variables 
(Table 7-1, with the exception of the PRISM score) which included 10 or more 
children that had been identified by a group of 61 Paediatric Intensivists in eight 
countries on three continents as influencing their decision to prescribe atropine.(248) 
Linearity in the log odds of continuous variables was assessed visually and by using 
likelihood ratio testing. 
 
Our primary end points were changes in mortality and a fall in heart rate from 
baseline to the lowest two R-R complexes during intubation. The secondary end 
point was the number of days from intubation to death.  
 
7.2.4  Statistical analysis 
Qualitative variables are described as numbers and percentages and quantitative 
variables as median [quartiles] or mean (standard deviation) according to their 
Gaussian distribution. Independent t-tests or a Mann-Whitney test were used for 
continuous data according to their distribution and Fisher's exact test was used for 
categorical data. All statistical tests were 2-sided and the probability of a type 1 error 
() was determined at <0.05. Univariate and/or multivariable linear or logistic 
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regression models were constructed to test the influence of atropine using the PS. 
Effect estimates were calculated for numerical variables and odds ratios (OR) for 
categorical variables with their corresponding 95% confidence intervals (95%CI). 
Pearson correlation was used to compare quantitative variables. Kaplan-Meier plots 
and Log-rank tests were used for survival analysis. Missing data were excluded list-
wise. All statistical tests were carried out using SPSS (version 19) with the exception 
of those concerning the PS which was performed using SAS V.9.2 software (SAS, 
Cary, NC).  
 
7.3  Results 
 
7.3.1  Study patients 
A total of 333 children were eligible for inclusion of which 277 were included. Fifty-
six children were not included and 13 children were excluded (Figure 7-1). A total of 
264 study patients were available for analysis (264/333, 79%) of which 114 from 
PICU and 150 from ICT. Twenty three Intensivists included a median of 5 [1-16] 
children each. 
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Figure 7-1; Flow-chart of inclusions, non-inclusions and exclusions. Neonates are 
<28 days and older children >28 days and less than 8 years. 
 
*ICT - Intensive Care Transport team positioned antenatally for premature births. 
 
7.3.2  Atropine use 
Atropine was prescribed in 124 of the 264 (47%) intubations and more frequently 
prescribed, although not significantly (p=0.08), during the intubations of neonates 
(79/153, 52%) that older children (45/111, 41%) (Table 7-1 and Figure 7-1). 
Atropine was prescribed significantly more frequently (p=0.01) by the ICT 
intensivists (81/150, 54%) than in PICU (43/114, 38%). The median frequency of 
atropine prescription per intensivist was 2 [1-8]. Two ICT intensivists with similar 
case loads were responsible for an important number of inclusions had diametrically 
opposed but balanced practices. One used atropine for 44 of 48 inclusions (92%) and 
the other for 5 of 49 inclusions (10%). The ante-natal positioning of the ICT team for 
extremely premature births, who were almost exclusively intubated without venous 
access, meant that the median gestational age of neonates without atropine was 32 
[IQR 30-37] compared to 38 [IQR 35-39] weeks for those given atropine (p<0.001).  
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Table 7-1; Population characteristics for all patients and the two age sub-groups of 
neonates and older children. All of the variables from the columns ‘All Patients’ 
were entered into the propensity score. The PRISM score was not included in the 
propensity score. Neonates are <28 days and older children >28 days and less than 8 
years. 
 
* p value <0.05 for the difference between the atropine and non-atropine groups 
NRD - neonatal respiratory distress, Non-NRD - non-neonatal respiratory distress, 
ENT - ear nose and throat, PRISM - Paediatric RISk of Mortality score. 
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7.3.3  Baseline characteristics and construction of the propensity score  
Only two of the variables of baseline pre-atropine prescription characteristics were 
significantly different between the atropine and no-atropine groups, these were the 
median age of patients (p=0.02) and the mean baseline heart rate (p=0.02). Three 
variables were not used in the construction of the PS because they featured in less 
than ten cases: fentanyl (n=1), thiopental (n=4) and vecuronium (n=4). The c-statistic 
of the PS was 0.72. When the two sub-groups were further subdivided into neonatal 
and older children age subgroups there was no significant difference between any of 
the variables. The PRISM score was retrospectively available for 94 of 111 older 
children and was not significantly (p=0.09) different between the atropine and non-
atropine groups (Table 7-1). The predicted risk of death of the older children, 
calculated from the PRISM scores, was 8% [3-30%] for the no-atropine group and 
5% [2-12%] for the atropine group (p=0.08). 
  
7.3.4  Mortality during intubation and during ICU stay 
Thirty-one children died during ICT/ICU care (11.7%, 31/264). There was 
significantly lower mortality in the neonatal group 6.5% (10/153) than for the older 
children 18.9% (21/111) (p=0.003). One child died during intubation giving an 
overall 0.4% mortality for the immediate intubation period (16 months old with a 
lethal chromosomal disorder, pulmonary hypertension and septic shock). No children 
were lost to follow up.  
 
The unadjusted mortality was 7.2% (9/124) for those who received atropine 
compared to 15.7% (22/140) for those who did not (OR 0.42, 95%CI 0.19-0.95 
p=0.04). When the association between atropine use and mortality was examined in 
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the age subgroups, there was a significant reduction of mortality in the older 
children, but not in the neonates (Table 7-3). The excess mortality in the older 
children who had not received atropine and had been intubated for non-
neonatal/cardiac/septic shock pathologies. The repartition according to pathology is 
presented in Table 7-2. 
 
Table 7-2; Breakdown of the causes of death by pathology. Neonates are <28 days 
and older children >28 days and less than 8 years. 
 
 
Table 7-3; The association between ICU mortality related to atropine use corrected 
by the propensity score (PS) in the two age subgroups. Neonates are <28 days and 
older children >28 days and less than 8 years. 
 
 
We conducted a post hoc analysis to consider the apparent association of absence of 
atropine treatment with death by using two PS constructed from the variables for 
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each age group. This was done to test the possibility that the construction of the PS 
from data from all children would be different if the PS was constructed using data 
from children of each age group. The association of atropine use with death remained 
relatively unchanged: post hoc PS adjusted OR in neonates of 2.4, (95%CI 0.56-10.4, 
p=0.23) and post hoc PS adjusted OR 0.24 (95%CI 0.06-0.96, p=0.043) for the older 
children. 
 
7.3.5  Survival analysis 
When atropine was used there was a significant difference in the survival distribution 
of the older children (p=0.005) but not the neonates (p=0.57) (Figure 7-2).  
 
Figure 7-2; Kaplan-Meier plots for mortality in the two age sub-groups of neonates 
and older children (7-2). 
 
 
7.3.6  Change in heart rate during intubation 
When atropine was used, the heart rate was a mean of 50 (45-55) beats/min 
(p<0.001) higher during intubation than when atropine was not used. After the 
administration of atropine the mean heart rate rose from 148 (126-170) beats/min to 
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166 (SD 147-185) beats/min (p<0.001) for the neonates and from 154 (124-184) 
beats/min to 174 (145-203) beats/min (p<0.001) for the older children (Figure7-3).  
 
Table 7-4; Multivariable analysis of the change in heart rate during intubation 
following fall in peripheral oxygen saturation (SpO2) and after the use of atropine 
(corrected by the propensity score [PS]). Neonates are <28 days and older children 
>28 days and less than 8 years. 
 
 
Figure 7-3.; Change in heart rate during intubation according to atropine use of the 
two age sub-groups. The central bar is the mean, the box represents the inter-quartile 
range and the whiskers the range. 
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Measured oxygen saturations were similar between atropine and non-atropine 
groups. Median fall in SpO2 was 25% [8-44] in the non-atropine group and 19% [6-
44] in the atropine group (p=0.31). There was a significant correlation between a fall 
in SpO2 and a fall in heart rate (p<0.0001) (Figure 7-4 and Table 7-4). The median 
number of attempts at intubation was also comparable between non-atropine (1 [1-2]) 
and atropine (1 [1-2]) (p=0.20) cases. One attempt at intubation significantly reduced 
mean heart rate in the neonates by 9.6 beats/min (95%CI 2.3-16.9, p=0.01) but not in 
the older children (6.1 beats/min
 
per intubation attempt, 95%CI 1.5-13.8, p=0.12). In 
multivariable analysis the number of attempts at intubation was not significantly 
different for either age group. Eleven children were excluded from the saturation 
analysis and 16 from the number of attempts at intubation because of missing data. 
 
Figure 7-4; Change in heart rate related to a change in peripheral oxygen saturation 
(SpO2) during intubation. The coefficient of determination is (r
2
) 0.10. 
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The use of the PS had little effect on the crude estimates of the mean change in heart 
rates which were 58.7 beats/min without the PS versus 53.4 beats/min with the PS 
for the neonates and 41.5 beats/min without the PS versus 40.8 beats/min with the PS 
for the older children. When the SpO2 and number of intubation attempts and 
atropine corrected by the PS were entered into a multivariable model only atropine 
and a fall in SpO2 remained significant (Table 7-4). 
 
7.4  Discussion  
 
We disproved our hypothesis and showed that the use of atropine was associated 
with less frequent ICU mortality but only in the older children. The decrease in ICU 
mortality was not a consequence of the reduction in intubation bradycardia which 
occurred in a similar measure in both age groups when atropine was not used.  
 
7.4.1  Study Population Bias 
Our population was diverse, with 57% of children being intubated and hospitalised 
outside the PICU of Robert Debré. This is similar to a 2004 survey in 204 French 
PICUs (165) and a 2010 report from UK neonatal units.(225) A recent survey of 
influences on atropine use and atropine prescribing habits among 61 paediatric 
intensivists in 8 countries noted that 49% prescribed atropine for half of their 
intubations.(16) One area where our practise differs from others is the relatively 
infrequent use of muscle relaxants including suxamethonium. This is due to the 
important proportion of neonates where hospital protocol does not recommend 
muscle paralysis, a relatively large proportion of ENT intubations and propofol use 
which is associated with good intubation conditions without relaxants.(273) 
 
139 
 
7.4.2  Frequency of Atropine Prescription 
The measured the frequency of atropine use in our population was 47% which is 
similar to that of one previous survey of activity in 204 French ICU units published 
in 2004 whereby that atropine was prescribed for 30% of neonatal intubations (<28 
days), 63% for infants (28 days to 23 months) and 18% for older children (165). 
Venkatesh et al. (225) recorded a 29% use of atropine in 93 neonatal units in the UK 
in 2010. A more recent survey of influences on atropine use and atropine prescribing 
habits among 61 paediatric intensivists in 8 countries noted that 49% prescribed 
atropine for half of their intubations.(248)  
 
7.4.3  Desaturation and Numbers of Intubation Attempts 
In our neonatal group of the median number of intubation attempts was 1 [1-2]. 
These results are analogous two other RCTs of neonatal intubation comparing a 
Morphine-Atropine-Suxamethonium (MAS) group and a propofol group (2, [1-3] 
versus 1, [1-2]) (211) and another study for a MAS pre-medicated group (1, [1-3]) 
versus a non-pre-medicated group (1, [1-6]) (224). Median trough oxygen saturation 
in our study was 76% which compares favourably to two neonatal RCTs which noted 
60% to 80% (211, 224) and in a prospective cohort of 58% to 65% (225).  
 
In one paediatric intubation study the mean number of attempts at intubation in a 
retrospective study was 1.6 per patient (20) compared to a mean of 1.9 in our study 
population. Carroll et al. (19) recorded a 23% prevalence of three of more attempts at 
intubation compared to our 7% frequency. The same study noted that desaturation 
below 90% occurred in 29% (40/137) of intubations (19). If we use an identical 
definition for our study population as many as 75% of the children were desaturated. 
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Fastle recorded a 22% (31/143) prevalence in hypoxaemia (without giving its 
definition) and noted that younger children were more susceptible to hypoxia (20). 
One previous anaesthetic study has also mentioned that age is an important risk 
factor for desaturation (4). There are two reasons to explain the difference in trough 
saturations between these studies and ours. Firstly, both Carroll (19) and Fastle (20) 
both highlight that their retrospective methodologies relied on accurate and honest 
recording in the intubation log and that this was a limitation. Secondly, our over one 
month population had a median age of 5.4 months, considerably lower than that of 
Fastle (12 months) (20) or Carroll (2.8 years) (19).  
 
7.4.4  Use of the Propensity Score 
We agree with Gayat et al. that emergency situations are a good example where 
recruitment patterns in RCTs may distort treatment effect and PS controlled cohorts 
may be preferable (284). However, we disagree with Gayat et al. when they 
recommend that matching on the PS should be the preferred method of using the PS 
(284). Matching assumes that the effect of treatment on the outcome is not different 
in those participants, treated or untreated, that could not be matched. The advantage 
of our choice of using a multivariable regression based model incorporating a PS is 
that all of the individuals can contribute to the final result. We chose a multivariable 
regression based model which provides more statistical power.(285) Our study 
design produced treatment groups of neonates and older children where there were 
no significant differences between pre-treatment variables (Table 7-1). This validates 
the use of the PS for which a considerable overlap in the distribution of variables is 
an a priori condition. In addition, our result for the crude OR for the mortality in the 
older children (0.21) remained stable when adjusted using the PS for the whole group 
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at 0.22 and was 0.24 for the post hoc divided PS. The effect of residual unidentified 
variables that were not entered into the PS could potentially have influenced the final 
result. Despite our result remaining significant when using a PS for all patients and 
divided for the two age groups, our result needs to be confirmed in a study using 
randomised methodology. 
 
There are three possible explanations for the unexpected significant difference in 
ICU mortality with and without atropine that we found both with and without case-
mix adjustment for atropine prescription using the PS. Firstly, the PS has not dealt 
with atropine prescription bias because not all prescription-influencing co-variates 
were included in its construction, which is a condition of its use (282), leaving 
residual confounders linking atropine prescription to death. A possible indication of 
this could be the non-significant difference in the PRISM scores of the atropine and 
non-atropine groups, which showed a trend towards an increased risk of death for the 
non-atropine group. The significant difference in the baseline heart rate between the 
two groups is integrated in the PRISM score and was also included in the PS before 
adjusting the final result. Secondly, that chance has produced a statistically 
significant result and finally that atropine may reduce mortality.  
 
The excess mortality we observed was not related to mortality during intubation 
because this was rare with only a single death observed. This rate is similar to 
previous series.(19, 20) Neither can the excess post-intubation mortality be ascribed 
to a late effect of bradycardia because this occurred with similar frequency in both 
the neonates and older children, yet the ICU mortality difference was only seen in the 
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older children. The pathologies that were associated with fewer deaths with atropine 
were principally Non-NRD and sepsis (Table 7-2).  
 
7.4.5  R-R Beat-to-Beat Variability 
One possible explanation for the observed association of atropine on mortality may 
be related the uncoupling of real-time feedback of measurements of blood pressure in 
the baroreceptors in the carotid bodies, which has the effect of reducing R-R beat-to-
beat variability (RRBBV). Vagal impulses are rapid by nature of the rapid 
hydrolysation of acetylcholine in postganglionic parasympathetic receptors contrary 
to sympathetic stimulation of the heart and vessels which is of the order of 2-5 
seconds.(286) Reductions in RRBBV following atropine administration have been 
measured in premature neonates awaiting intubation for respiratory distress (287) 
and normal children undergoing routine anaesthesia.(173) In small children, 
reductions in RRBBV could be achieved by a single dose of atropine due to its long 
half-life (288) which is a consequence of the extended elimination phase resulting 
from its increased distribution volume (289). 
 
Pre-terminal haemodynamic decompensation is frequently accompanied by 
bradycardia in children.(290) It results from a 'two-hit' process whereby the first step 
is often exaggerated RRBBV before the second step of entry into a negative feedback 
loop of arrhythmia and hypoperfusion, as has been demonstrated experimentally in 
dogs.(291) The short-lived intubation bradycardia commonly observed in our non-
atropinised patients is an example of severe RRBBV, yet intubation mortality was 
rare because the children were still self-protecting from the second stop of 
bradycardia-hypoperfusion. Atropine is ineffective against hypo-perfusion and non-
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vagally mediated bradycardia when they are already established, indeed atropine is 
no longer recommended by the AHA for resuscitation.(292) However, when atropine 
is prophylactically administered before bradycardia-hypoperfusion, as happened to 
our atropinised older patients, some of whom later became vulnerable to 
haemodynamic decompensation, atropine could protect against the first step of 
spontaneously occurring exaggerated RRBBV.  
  
7.5  Conclusions 
 
Atropine was associated with a reduction in ICU mortality outside the immediate 
period of the intubation only in children aged over one month. This effect is 
independent of its capacity to reduce heart slowing during intubation. The 
association between atropine use during CCI and reduced ICU mortality should be 
investigated in other populations using prospective randomisation.  
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Chapter Eight 
An Animal Intubation Model of Vagally Induced Changes in 
 Blood Pressure during Hypovolaemia and Endotoxaemia 
____________________________________________________________________ 
 
8.1  Introduction 
 
The intubation of children during critical illnesses can provoke alterations in both 
heat rate (19, 20) and blood pressure.(9, 224) The physiological stimulation of the 
Vagus nerve by hypoxaemia in the aortic bodies (7) and manipulation of the 
laryngopharynx during laryngoscopy releases acetylcholine in the sino-atrial node.(8) 
Intubation-related vagal stimulation is accompanied by selective vasoconstriction 
which conserves atrial pre-load and therefore ventricular filling.(114-117). In 1984 
Marshall et al.(9) noted a rise in blood pressure in a group of newborns who 
experienced significant bradycardia during intubation. 
 
There are two other influences on haemodynamic instability during intubation; drugs 
and pathology. Induction drugs, such as propofol(6, 177), thiopental(177), 
morphine(180), sufentanyl(179) and remifentanil(178), may also induce bradycardia. 
Unlike vagal bradycardia this is typically accompanied by vasodilatation. 
Vasodilatation is potentially detrimental because it lowers atrial pre-load with a 
negative impact on ejection volume and therefore cardiac output. Septic shock in 
adults (84, 293) is typically associated with vasodilatation. In contast early 
hypovolaemic is associated with vasoconstriction.(90) 
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The consequences of the above effects on haemodynamic stability during routine 
anaesthetic intubation are almost always insignificant. However the interactions 
between these pharmacological and physiological mechanisms producing bradycardia 
and the physiology of acute critical illness mean that intubation presents a significant 
risk of death in critically ill adults (3, 16, 18) and children.(4) Mean blood pressure 
has a tendency to fall by 30mmHg during intubation in adults and those who start the 
procedure with hypotension are particularly at risk of haemodynamic 
deterioration.(3) One recent review has suggested that bradycardia in the presence of 
vasodilatation during intubation may destabilise haemodynamic homeostasis.(270)  
 
The animal model was used to test the hypothesis that blood pressure changes after 
vagal stimulation are not modified by hypovolaemia or endotoxaemia. Preliminary 
animal experimentation at the national veterninary school near Paris established a 
model of intubation in rabbits. Mechanical stimulation of the laryngopharynx was 
unable to reliably induce changes in blood pressure even in the presence of severe 
hypoxia. However, electrical stimulation of the laryngopharynx of a rabbit using a 
modified ETT did produce changes in blood pressure but only at an intensity of 
electric current whereby the muscles of the whole of the upper body contracted. 
When the Vagus nerve was dissected out and stimulated directly using an electrical 
current changes in blood pressure were consistently produced (results not shown). 
The rabbits were anaesthetised with intra-venous urethane because of its single dose 
regimen, good analgesic and anaesthetic properties and previously established 
minimal effects on haemodynamic function in the experimental situation.(294) 
Direct measurement of the blood pressure in the right carotid artery using an iWorx 
214 monitor was favoured because of its reliability in measuring changes in blood 
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pressure at low and rapidly changing pressures and in combination with rapidly 
changing heart rate (results not shown).  
 
In addition we examined the levels of circulating catecholamines and their 
relationship to blood pressure in response to during the two pathological states. 
 
8.2  Methods 
 
8.2.1  Experimental Protocol 
The study was approved by the ComEth Anses/ENVA/UPEC (Comité d’Ethique 
pour l’Expérimentation Animale, Maison-Alforts, FRANCE). Male New Zealand 
White (NZW) rabbits were obtained from Hypharm, La Corbière, 49450, Roussay. A 
maximum of 15 rabbits were maintained in a pen of 3m wide by 4m long and of a 
height of 3m with a dense layer of straw and hay, which is in excess of animal 
husbandry recommendations.(295) The pen was situated in a room of 15m by 12m 
with several large windows giving access to daylight and at least one window 
continually open to ensure aeration. Food and water was provided ad libitum.  
 
Male New Zealand White rabbits were anaesthetised by the injection urethane in a 
marginal vein of an ear. A midline incision was made in the anterior aspect of the 
neck and the trachea opened before being intubated. The right carotid artery was 
cannulated with a 22gauge canula and the left Vagus nerve exposed. Continuous 
mean blood pressure readings and intermittent blood gas measurements were made. 
The rabbits were entered into the experiment when blood pressure had been stable 
for at least 15 minutes. The arterial pH was required to be between >7.35 and <7.45 
(normal limits of rabbit pH 7.2-7.5(296, 297)).  
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The rabbits were randomly assigned into four groups; control (11 rabbits), 
endotoxaemia 1mg/kg (LPS from E.Coli B:055, Sigma-Aldrich, France) (11 rabbits), 
hypovolaemia 20% reduction in blood volume (8 rabbits) and hypovolaemia 
reduction in blood volume of 40% (8 rabbits).  
 
Rabbits in the hypovolaemia groups were bled over a period of five minutes from the 
carotid artery catheter 20 minutes after baseline according to an estimation of the 
blood volume of 5.5ml of blood per 100g of body weight.(298, 299) The rabbits 
assigned to the endotoxaemia group were injected with 1mg/kg of endotoxin diluted 
at 1mg/ml in 0.9% saline solution at a rate of 2mg/5minutes. 
 
8.2.2  Blood Sampling and Biochemical Analysis 
Sampling was performed at the following times; baseline, 30, 60, 90, 120, 150, 180, 
240 and 300 minutes, hypovolaemic shock baseline 30, 60, 90, 120 and 150 minutes, 
endotoxic shock baseline, 30, 60, 90, 120, 150, 180, 240 and 300 minutes (Figure 8-
1). The samples taken from the endotoxaemic rabbits at 30, 90 and 150 minutes were 
not analysed, as according to protocol, so as to ensure identical experimental 
conditions for all groups.  
 
Samples of 1.3ml of blood were drawn from the carotid artery of the anaesthetised 
rabbits. Seventy microlitres were separated for blood gas (pH, PCO2, base excess, 
bicarbonates) and serum lactate analysis using an i-STAT® (Abbott Point of Care 
Inc., 400 College Road East, Princeton, NJ 08540, USA). Normal ranges were as 
follows; lactate (normal range 1.0mmol/l (0.5-1.5])(300), haematocrit (NZW normal 
range 31.3-43.3% [mean weight of rabbit 3.6kg [3.0-4.2kg])(301). A haematocrit 
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was determined by placing 0.1ml of whole blood in a heparin coated plastic tube 
(100µl safeCLINITUBES, Radiometer Medical AsP, Akandevej 21, 2700 Bronshoj, 
Denmark), centrifuged at 2000 revolutions/minutes for two minutes and the relative 
proportion of serum and compacted cells compared. The remaining 1.1 ml was 
transferred into an EDTA tube of 1.3ml, shaken gently before centrifugation at 
4000rpm at a temperature of 4°C for 5 minutes. Thereafter, the plasma was drawn off 
and transferred directly for storage at -20°C in the dark for later catecholamine 
analysis.(302, 303) 
 
8.2.3  Stimulation of the Vagus Nerve 
The Vagus nerve was lifted free from other structures in the neck, laid across two 
steel electrodes 5mm apart and electrically stimulated using a 3.0mA current, 250 
pulsations of 10milliseconds at 10Hz (duration of stimulation 25 seconds). 
Stimulations were made at baseline, 30, 45, 60, 75, 90, 115, 120, 135, 150, 165, 180, 
210, 240, 270 and 300 minutes for the controls and endotoxaemia models and 
baseline, 30, 45, 60, 75, 90, 115, 120, 135, 150 minutes for the hypovolaemic model 
(Figure 8-1). This allowed the control rabbits to serve for the hypovolaemic and 
endotoxaemic rabbits but meant that the endotoxaemic rabbits received five more 
stimulations and three more blood samplings than would otherwise have been 
necessary. A three-minute interval was left after taking blood before a vagal 
stimulation. 
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Figure 8-1; Gant chart showing schema of blood sampling. Control rabbits and the 
experimental groups all received the same number of stimulations and blood 
samples. Endotoxaemic rabbits had five stimulations and three blood samples that 
were not analysed, as according to protocol, so as to ensure identical experimental 
conditions for all groups. 
 
 
8.2.4  Catecholamine analysis 
All catecholamine analysis was performed at the Hôpital Robert Debré. The process 
of catecholamine analysis takes place in four discrete stages; sampling, purification, 
chromatography and quantification of the analyte and was carried out in accordance 
with the reverse-phase ion-pairing liquid chromatography methodology described by 
Candito et al. in 2002.(157)  
 
Preparation of solution buffer solution. Buffer EDTA pH8.6 (2M, EDTA2%). 12.11g 
of tris base was added to 1g of EDTA and brought to a volume of 50ml using sodium 
hydroxide to maintain a pH of 8.6. 
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Preparation of washing solution. Buffer EDTA pH 8.1 (0.33M, EDTA 2%). 2g of tris 
base was added to 20g of EDTA and brought to a volume of 1000ml using sodium 
hydroxide to maintain a pH of 8.1. 
 
Preparation of eluate (mobile phase). One millilitre of glacial acetic acid 
concentration 175mM (approximately pH2.0) with 50µL of 5%EDTA solution was 
added to make a volume of distilled water to bring to a volume of 100ml. 
 
Preparation of control standards. Ten ampoules of 2.5ml CP Plasma Calibration 
External standard were obtained from Chromosystems (Chromosystems Instruments 
and Chemicals GmbH, Heimburgstrasse 3, 81243 München, Germany). Each 2.5ml 
ampoule was reconstituted with 2.5ml of distilled water, aliquotted into 500µl 
quantities in 2ml eppendorf containers and frozen at -40°C. The relative 
concentrations of catecholamines were; noradrenaline 6.86nM, adrenaline 1.59nM 
and dopamine 2.80nM. 
 
Preparation of internal control. 50µl of dihydroxybenzoic acid (DHBA) derived from 
urinary catecholamines diluted was diluted in 1/100 in tris EDTA pH8.6. 
Dihydroxybenzoic acid is manufactured from a catechol ring and has the property of 
not interfering with plasma derived catecholamines in the mobile phase (Figure 8-2). 
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Figure 8-2; 2,5-Dihydroxybenzoic acid is used as the internal control during high-
performance liquid chromatography for the detection of catecholamines as it does not 
interfere with the mobile phase. (http://en.wikipedia.org/wiki/2,5-Dihydroxybenzoic_acid) 
 
 
 
The plasma was removed from -40°C storage and thawed at room temperature. Six 
hundred microlitres was drawn from the plasma samples and 20mg of alumina 
(aluminium oxide, Al2O3) and 100µl of the internal standard were added to the 600µl 
of plasma. The mixture was gently agitated for 5 minutes by hand before 
sedimentation of the alumina by centrifugation at 5000rpm for 2minutes. The 
supernatant was drawn off and discarded.  
 
The samples were washed by the addition of 1ml of the washing solution. The 
mixture was gently agitated by hand for 3 minutes before being centrifuged at 
5000rpm for 2minutes. The supernatant was drawn off and discarded. The process as 
repeated two more times. 
 
A total of 100µl of buffer solution was added to the alumina in an eppendorf 
container, which was agitated by hand for 5min to liberate the catecholamines. The 
mixture was centrifuged at 5000rpm for 5 minutes. Fifty microlitres of the 
supernatant were removed and added to 100µl glass microtubes for injection through 
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a 717 Waters auto-sampler onto a C18 Purospher (Merck) column (150x4 mm, 4µm) 
equipped with a guard column. The aqueous isocratic mobile phase adjusted to pH 
3.9 consisted of citric acid 20mM, sodium acetate 50mM, sodium heptane sulfonate 
0.4mM in methanol 10%. Mobile phase was pumped at a flow rate of 1ml/min by a 
Waters Model 550 pump.  
 
Quantification of the catecholamines was carried out by electrochemical detection. 
The catecholamines were eluted from the column using an amperometric 2465 
Waters detector set at 0.5V. An external control of known concentrations of 
noradrenaline, adrenaline and dopamine was used to calibrate the internal control 
against the samples tested. The area under the curve of each peak detected by the 
chromatograph is used to compare the area under the internal control. In turn the area 
under the internal control was compared to the area under the curves of the standard 
of known concentration. Millennium Waters Empower Chromatography software 
was used for all calculations. Fifteen to 25 samples were batched for analysis. A 
negative control (acid), internal control (urine catecholamine) and standard control 
(plasma catecholamine) were analysed in sequence before each batch. 
 
The severity of pathology was determined by the time to the first death in each 
group. The readings immediately prior to the first death in each group were used post 
hoc as the start point and the end of experimentation was one hour later.  
 
8.2.5  Statistical analysis 
Qualitative variables are described as numbers and percentages and quantitative 
variables as median [quartiles] or mean (standard deviation) according to their 
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Gaussian distribution. An independent t-test, or a Mann-Whitney test, was used for 
continuous data according to their distribution. All statistical tests were 2-sided and 
the probability of a type 1 error () was determined at <0.05. All statistical tests were 
carried out using SPSS (version 19). 
 
8.3  Results 
 
8.3.1  Baseline Characteristics 
There were no significant differences between the weights of the rabbits in the 
control group (mean 1.96kg) compared to the endotoxin (mean 1.93kg, p=0.62), 20% 
hypovolaemia (mean 1.91kg, p=0.55) and 40% hypovolaemia (mean 1.87kg, p=0.28) 
groups. Nor were there differences in the baseline characteristics of pH, CO2, HCO3, 
base excess, lactates, haematocrit and the baseline haemodynamic parameters of 
mean blood pressure, heart rate, pulse pressure and change in mean blood pressure 
following vagal stimulation for the control group compared to the other three groups 
(Table 8-1).  
 
Whilst there was no significant difference in the baseline adrenaline, noradrenaline 
and dopamine between the control groups and the two hypovolaemia groups, the 
baseline levels of adrenaline and noradrenaline were significantly higher in the 
endotoxin group (median control adrenaline 2.0nM[0-5.2] versus median endotoxin 
adrenaline 7.9nM[4.3-9.0], p=0.005; median control noradrenaline 0.nM3[0-1.6] 
versus median endotoxin noradrenaline 1.5nM[0.6-2.4], p=0.04) (Table 8-1).  
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Table 8-1; Median baseline biochemical, haematologic and hormonal characteristics 
of the four groups of rabbits; control; endotoxin, and the two hypovolaemia groups 
(20% and 40%).  
 
* p<0.05, ¤ p<0.01 
 
One rabbit from the 40% hypovolaemia group died after bleeding and before 
stimulation and was excluded. The first death after vagal stimulation after the start of 
experimentation in the HV40% group occurred between +15 and +30 minutes from 
bleeding and between +240 and +270 minutes from injection in the endotoxin group. 
As such the comparison of the biochemical, haematological and change in mean 
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blood pressure following vagal stimulation was from +15minutes in the 
hypovolaemia groups and +240 minutes for the endotoxin group. There were two 
deaths in the HV40% group (2/7, 29%) and three in the endotoxin group (3/11, 27%) 
in the 60 minutes of experimentation. No rabbits died in the HV20% group.  
 
Table 8-2; Median changes in biochemistry and haematocrit in the hypovolaemic 
rabbits. 
 
 * p<0.05, ¤ p<0.01 
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8.3.2  Changes in Biochemical and Haematological Parameters in  
  Hypovolaemia 
The hypovolaemia groups showed significant decreases in pH, CO2, HCO3, base 
excess, lactates and haematocrit compared to the control group (Table 8-2). These 
changes were proportional to severity of hypovolaemia. 
 
A significant increase in adrenaline was observed in the 40%, but not the 20%, 
hypovolaemia group at time t=+45minues compared to the controls (Table 8-3). 
There was a non-significant trend for the 20% group to have higher levels of 
noradrenaline that the 40% group (Table 8-3). 
 
Table 8-3; Median changes in catecholamines for the control and hypovolaemia 
groups. 
 
 * p<0.05, ¤ p<0.01 
 
 
157 
 
8.3.3  Changes in Biochemical and Haematological Parameters in  
  Endotoxaemia 
In the endotoxin group there were significant decreases in CO2, HCO3 and base 
excess, no change in pH, lactates and haematocrit and significant increases in 
noradrenaline (Table 8-3). 
 
Table 8-4; Median changes in biochemistry and haematocrit in the endotoxin group.  
 
* p<0.05, ¤ p<0.01 
 
The levels of noradrenaline were significantly higher in the endotoxin group at +240 
and +300 minutes and although levels of adrenaline were higher there was no 
significant difference from the control group (Table 8-5). 
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Table 8-5; Median changes in plasma catecholamines in the endotoxin group.  
 
* p<0.05, ¤ p<0.01 
 
8.3.4  Changes in Haemodynamic Parameters 
The haemodynamic parameters of pulse pressure, mean blood pressure and heart rate 
all fell significantly and in proportion with blood loss in the hypovolaemic groups 
(Figure 8-3). There were no significant changes in any of these vital signs in the 
endotoxin group (Figure 8-3).  
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Figure 8-3; Changes in haemodynamic parameters for the control; hypovolaemia 
and endotoxaemia rabbits. The central bar is the mean, the box represents the inter-
quartile range and the whiskers the range. Significant differences between the control 
and experimental groups of p<0.05 are noted by an '*' and p<0.01 by an '¤'. 
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Mean blood pressure fell in control rabbits with vagal stimulation.  Mean blood 
pressure fell less in rabbits with hypovolaemia (Figure 8-4). There was a dose effect 
for the two levels of severity of hypovolaemia. There was a trend for mean blood 
pressure to fall in a similar manner in endotoxaemic rabbits compared to controls 
(Figure 8-4). 
 
Figure 8-4; Fall in mean blood pressure following vagal stimulation prior to the first 
death. Note, the times from the start of experimentation are different for the 
hypovolaemia (+15, +60 and +75 minutes) and endotoxin (+240 and +300 minutes) 
groups. The central bar is the mean, the box represents the inter-quartile range and 
the whiskers the range. Significant differences between the control and experimental 
groups of p<0.05 are noted by an '*' and p<0.01 by an '¤'.                 
       
8.3.5  Relationship between Catecholamines and Fall in Mean Blood  
  Pressure 
In pooled results of all rabbits there was an inverse relationship between adrenaline 
concentration and the absolute value of the fall in mean blood pressure in response to 
stimulation.  No such association was detected with noradrenaline (Figure 8-5).  
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Figure 8-5; Levels of log
10
adrenaline and noradrenaline compared to fall in mean 
blood pressure following vagal stimulation. 95% confidence intervals are shown as 
dotted lines. The coefficients of determination (r
2
) were 0.11 for adrenaline and 0.03 
for noradrenaline. 
   
 
8.4  Discussion 
 
We disproved our hypothesis and determined that vagal stimulation during 
hypovolaemia in our model was significantly associated with a protection from fall 
in mean blood pressure when compared to controls. There was no significant 
difference the fall in mean blood pressure in endotoxaemic rabbits compared to controls 
 
8.4.1  Experimental Bias 
All four experimental groups witnessed raised levels of circulating baseline 
catecholamines which were probably due to the stress of anaesthetic induction and 
surgical preparation. In particular, the levels of circulating adrenaline and 
noradrenaline were significantly higher in the endotoxin group at baseline than for 
the controls (Table 8-5). It has previously been established that conditions of stress 
increase catecholamine production and this may be a sign that the rabbits were 
improperly anaesthetised despite each being tested for paw and corneal 
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reflexes.(303) However, the preparation was identical in all cases. In addition, the 
plasma samples were analysed in the same order that the rabbits were entered into 
the experiment. This finding was probably due to chance but is an important bias for 
the comparison of the endotoxin and control groups during the course of the 
experiment. Nevertheless, it should be noted that, despite the higher levels of 
circulating catecholamines the baseline, the heart rate, mean blood pressure and 
lactates were generally lower in the endotoxin group which is contrary what might 
have been expected (Figure 8-3 and Table 8-4).  
 
We deliberately chose young animals to ensure that they resembled, in as much as 
possible, the level of immaturity of the autonomic nervous system in human children 
whilst not complicating the surgical preparation.(113) Although it is probable that 
the rabbits reached a stage of autonomic maturity at an earlier age.(304)  
 
We sampled 11-14% of blood volume in our experiment and this was probably 
responsible for the decline in median haematocrit from 42[37-45] to 40[37-43]. This 
may have had an influence on haemodynamic homeostasis but was identical for all 
groups (Table 8-2 and 8-4). 
 
8.4.2  Anaesthetic Considerations 
Because our experimental protocol involved important surgical intervention the 
animals were maintained in a state of general anaesthesia throughout. Unfortunately, 
anaesthetics have effects on haemodynamic and biochemical parameters.(294, 305) 
We chose urethane as an anaesthetic because of its effective analgesia, its single dose 
regimen and because it has previously been established to have minimal effect on 
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haemodynamic parameters in anaesthetised rats.(294) Another advantage of using 
urethane is that the animals remained spontaneously breathing which resembles the 
clinical situation when children are first diagnosed with hypovolaemic, although to a 
lesser extent, for septic shock.  
 
When using urethane in the control rabbits, pH, pCO2, base excess, lactates and 
haematocrit remained constant or relatively little changed. However, despite mean 
blood pressure being sustained during the course of the experiment heart rate fell 
progressively notwithstanding the accompanying increases in noradrenaline and 
adrenaline. This result has been previously observed in rats when using 
urethane.(294)  
 
8.4.3  Models of Critical Illness 
Our model of hypovolaemia demonstrated changes in both biochemical and 
haemodynamic parameters, with the exception of heart rate which decreased (Table 
8-2 and Figure 8-3). Normally tachycardia is present during hypovolaemia but 
bradycardia is also observed in human models where reduced pre-load is 
compensated for by a prolongation of diastole which allows better ventricular 
filling.(306)  
 
Classically the effect of hypovolaemic shock on haemodynamic integrity is biphasic 
and asymmetric. Mean blood pressure is maintained during the early compensatory 
(Phase I) and heart rate rises due to baroreceptor induced vasoconstriction.(90, 91) 
This is followed by a decompensatory (Phase II) which sees a fall in mean blood 
pressure and heart rate associated with a fall in vascular resistance.(90, 91) Phase I is 
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accompanied by a fall in cardiac output during the maintenance of mean blood 
pressure whereas Phase II is accompanied by maintenance of cardiac output and fall 
in mean blood pressure. Initially myocontractile force is maintained or slightly 
improved but diminishes in as shock persists.(307) In our experiment, mean blood 
pressure fell markedly after bleeding in the 40%HV model, then increased 
(vasoconstrictive Phase I) before reaching a plateau and then falling (vasodilatory 
Phase II) (Figure 8-3).    
 
The situation of the endotoxaemic rabbits was more complex. A metabolic acidosis, 
as exhibited by significant decreases in bicarbonates and base excess, was induced. A 
normal pH was maintained through compensating by hyperventilation which reduced 
pCO2. Whilst there were no significant differences in heart rate and pulse pressure 
the mean blood pressure of the endotoxic rabbits compared to the controls (Figure 8-
3) and the lactate levels did not increase, which is an effect that has been previously 
observed by Lobo et al..(308) The baseline higher levels of adrenaline and 
noradrenaline may be in part an explanation for this. The baseline level of adrenaline 
fell rapidly in the control group whereas that for noradrenaline remained significantly 
higher and this may be a true manifestation of endotoxic shock. Despite the relative 
paucity of biochemical and haemodynamic changes in the endotoxin group three of 
the 11 rabbits died. There were no deaths among the controls.  
 
Brierley et al. used physical characteristics of perfusion in children to characterize 
septic shock which would not have been pertinent to our model.(34) The most 
appropriate animal model of human septic shock is subject to conjecture.(309) That 
so many models have been proposed indicates that no one model clearly reproduces 
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human septic shock. Our aim by using an intravenous dose of endotoxin was to 
obtain maximum harmonisation of experimental conditions. In the clinical situation 
there is rarely an explosive release of cytokines, as intended in our model, but a more 
gradual inflammatory response. The dose of endotoxin (1mg/kg) was intended to be 
rapidly lethal within the time period of the experimental protocol whilst producing 
similar changes in biochemical, hormonal and physiological parameters to other 
studies.(310) Other studies have described statistically significant falls in mean blood 
pressure and heart rate from as early as 1-2hr after injection in rabbits (1mg/kg)(308) 
and dogs (1.5mg/kg).(311)  
 
8.4.4  Mean Blood Pressure in the Models after Vagal Stimulation 
Our principal objective was to ascertain whether there was a differential reaction in 
blood pressure to vagal stimulation in the two models of pathology and in this we 
were successful. The reaction of the hypovolaemic rabbits compared to the control 
rabbits was to maintain, and sometimes, increase blood pressure during vagal 
stimulation. The reaction to vagal stimulation of the endotoxic rabbits was similar to 
controls (Figure 8-5).  
 
Serum levels of noradrenaline were higher in the endotoxic rabbits (Table 8-5) but 
were unable to protect their blood pressure during vagal stimulation (Figure 8-4). 
This is surprising because noradrenaline has an action that is both vasoconstrictive 
and inotropic.(152) This is indicative of a failure of the action of noradrenaline. In 
contrast, higher levels of adrenaline were associated with protection from vagal 
stimulation (Figure 8-5).  
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8.5  Conclusions 
 
Hypovolaemia protected rabbits from fall in mean blood pressure during vagal 
stimulation. This effect was proportional on the degree of hypovolaemia. The 
endotoxin group had a similar mortality rate as that for the HV40% group. Higher 
levels of baseline catecholamines in the endotoxin group introduced bias. Mean 
blood pressure fell during vagal stimulation in the endotoxin to a similar degree than 
in the control group. Pathology can have an effect on blood pressure change during 
vagal stimulation in this model of intubation.   
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PART THREE 
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Chapter Nine 
Discussion 
____________________________________________________________________ 
 
Intubation during critical care illness can be regarded as a 'challenge' to survival with 
bradycardia and low blood pressure being associated with reduced survival in 
adults.(3, 17) This general aim of this thesis is to examine instability in these two 
haemodynamic parameters during the intubation of critically ill children. 
 
9.1  Principal Sources of Bias 
 
The Delphi survey revealed a striking lack of consensus regarding several indicators 
of atropine prescription and was moreover unable to generate consensus. The Delphi 
survey achieved a good mix of experience in all three users groups and was 
successful in recruiting Intensivists from eight different countries on three continents, 
which is in excess of that habitually encountered.(252) Set against this is the 
relatively high proportion of French Intensivists. Had a more exhaustive recruitment 
been concentrated on three countries, perhaps France, the United Kingdom and the 
United States, it possible that differences between influences on atropine prescription 
and opinions would have been generated. Opinions regarding atropine prescription 
are not only firmly held but are very little modified by the opinions of others. This is 
paradoxal in that relatively little information has been published concerning the use 
of atropine for CCI. 
 
The ECG study, Chapters 5-7, furnished a large quantity of data from a critical care 
setting where few data are available. An important source of bias was created by pool 
of Intensivists having been drawn exclusively from one centre. This allowed 
169 
 
unrepresentative prescription practices, such as the infrequent use of muscle 
relaxants, to mitigate against the generalisability of the results. Although the author 
can confirm that this is a practice that is general in the Paris Region this cannot be 
said of other countries such as the United States and the United Kingdom. Another 
example of bias is the relatively low number of children with cardiac disease who 
were included, the Hôpital Robert Debré being without a cardiac surgery unit. 
 
No adjustments were made for case-mix bias in the ECG study during the estimation 
of the number of lost beats or incidence of arrhythmias and conduction disturbances. 
The propensity score is a valuable tool to retrospectively adjust for differences in the 
study groups but may be insufficiently convincing to Intensivists for them to decide 
on the potential merits of atropine. Prospective randomisation would have improved 
external validity but may have had important effects on recruitment patterns. A 
randomised, placebo-controlled trial is needed to resolve the question of atropine use 
and intubation/ICU mortality. 
 
The use of direct electrical stimulation to the Vagus nerve in the animal model 
involved a number of compromises. The approach was necessary because of the 
failure to achieve reliable changes in blood pressure by mechanical stimulation of the 
laryngopharynx even in the presence of hypoxaemia. A residual effect on blood 
pressure was noted when the lower portion of the Vagus nerve was stimulated in 
rabbits pre-treated with atropine (results not shown). This indicated that not all of the 
effect of the electrical stimulation on blood pressure was mediated by the Vagus 
nerve. In addition, the significant surgical preparation of the rabbits induced the 
production of adrenaline and noradrenaline. The differences in baseline production of 
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catecholamines in the hypovolaemia group of rabbits compared to the controls and 
endotoxin group make the interpretation of the blood pressure results complex. It is 
possible that blood pressure was artificially maintained during vagal stimulation in 
the endotoxin group due to the elevated baseline production of catecholamines. 
 
9.2  The Clinical Outcome of Death 
 
Although the collective opinion of the 61 intensivists who participated in the Delphi 
survey was unequivocal that there is a risk of death during CCI (82%, median 8[7-9]) 
we found intubation mortality to be comparatively low (0.4%). Indeed, two other 
paediatric studies involving 280 intubations did not report any deaths.(19, 20) When 
contrasted to the frequency of death reported in adult studies we could have 
anticipated 3-9 deaths during intubation.(3, 16) Such low intubation mortality, even 
in studies with relatively large sample sizes as ours, does not allow deductions to be 
made regarding possible risk factors.  
 
Despite severe reductions in blood pressure prior due to hypovolaemia and severe 
reductions in blood pressure during vagal stimulation, none of the rabbits died during 
vagal stimulation. As such the experimental model would not be a valuable tool to 
investigate intra-intubation mortality. 
 
Our finding that atropine may protect from ICU mortality in children aged over one 
month but not in neonates is difficult to explain. The difference between the ICU 
mortality cannot be ascribed to intubation bradycardia because this occurred at the 
same frequency in the neonates and older children although death occurred rarely 
during intubation. Despite the PS being validated exactly for this our methodology 
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the PS can only adjust for bias when the variables that are responsible for the bias are 
included in the PS. As such our surprising result will need to be investigated by a 
randomised controlled trial. 
 
9.3   Heart Rate 
 
Whether heart rate falls or not during intubation was not asked during the Delphi 
survey, Chapter 4, because numerous anaesthetic (4, 7, 8, 10, 12, 13, 22, 162) and 
critical care (9, 19-21, 224, 225) articles effectively deal with the subject.  
 
Our ECG study confirmed previous findings that bradycardia occurs in a similar 
manner in neonates, children over one month and during further intubations. 
Previous articles have not differentiated between age groups using the same cut-off 
of more or less than four weeks. The transition from a dominant parasympathetic 
system to autonomic co-dominance in the first few months of life should 
theoretically result in higher levels of bradycardia in the neonates.(113) This was 
reflected by the Delphi survey which revealed that the age of the children did have an 
influence on atropine prescription. As such it was surprising that the fall in heart rate 
was very similar between the age groups. The distribution of the age of the children 
meant that although the median age of the children over four weeks of between 134 
and 225 days. As such, even the older children could be considered to be influenced 
by predominant parasympathetic activity. The data do not allow us to separate the 
influences of vagal activation and drugs but it is possible that the bradycardia 
witnessed in the younger children was mostly induced by vagal stimulation and that 
observed in the older children was due to the effects of the anaesthetic drugs used for 
intubation.  
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The message from the lost beat algorithm is that whilst heart rate falls frequently 
during intubations and is unlikely to be of consequence if less than 50beats/min. A 
fall in heart rate of less than 50beats/min is reassuring but if the heart rate falls by 
more than 50beats/min it is no longer possible to extrapolate possible risk of 
haemodynamic decompensation (as defined by use of adrenaline, cardiac massage, 
fluid boluses or death). This is an important finding for clinical practice and could 
guide clinicians. Although no evidence has been presented in this thesis to say that a 
loss of 781 beats compared to 14 beats is of greater risk for haemodynamic 
decompensation, it would be counter-intuitive to assert that the risks are equal. 
Intubation records that note that the lowest heart rate fell by more than 50 beats/min 
from baseline are unlikely to be unable to demonstrate the risk to haemodynamic 
function. The addition of an algorithm to monitoring equipment may enable better 
prediction between loss of heart beats and haemodynamic decompensation. 
 
9.4  Arrhythmias and Conduction Abnormalities 
 
Bradycardia has been shown to be associated with arrhythmias and conduction 
disturbances. The overall frequency of arrhythmia and conduction abnormalities was 
higher for the older children despite similar levels of bradycardia being observed. 
There were two important differences between the two groups which may account 
for this observation. Firstly, the arrhythmogenic properties of the anaesthetics that 
were most frequently used in the older children and secondly, that the pathologies of 
the older children which are a potentially greater risk for instability of the pacemaker 
and conducting systems of the heart. 
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The results presented in this thesis do not enable deductions to be made regarding 
changes in blood flow during these episodes. However, any dys-coordination of 
myocardial conduction and/or depolarisation of myocytes will have effects on flow 
would be above and beyond those related to simple bradycardia at the same heart 
rate. In addition, acute bundle branch block, Mobitz type II conduction abnormalities 
and/or sinus pause with ventricular escape are risks for cardiac arrest.(280) 
 
9.5  Hypotension 
 
Studies of adult intubations demonstrate that blood pressure falls during 
intubation.(3, 17) Pre-intubation shock increases the risk of death during 
intubation.(3) In contrast, studies in neonates have reported increases in blood 
pressure during intubation.(9, 211) Caution must be exercised when comparing these 
studies as several important differences are apparent. Firstly, the neonates in these 
studies received proportionately less hypotension-inducing drugs and secondly, the 
neonates were intubated for neonatal respiratory distress and not for shock. For 
instance, Griesdale et al.(17) recorded 21% of cases as having a low systolic blood 
pressure (<90mmHg) prior to intubation and 23% of cases already being maintained 
on vasopressors.  
 
The Delphi survey was unable to reach a consensus that hypotension occurs during 
intubation (74%, median 8[6-9]) principally because the intermediate users were not 
in agreement (61%, median 7,5[6-9]). This is perhaps surprising when viewed in the 
context of the Infrequent Users, who replied negatively to most the statements but 
were in agreement over this statement (79%, median 9[7-9]). It is possible that the 
Intermediate Users, who were described as being 'Discerning Users' in Chapter 4, 
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interpreted the statement as being ambiguous. Whilst neonates may not experience a 
fall in blood pressure during intubation, the pathologies for which the older children 
were intubated resemble much more closely adult type pathologies.  
 
The animal model unexpectedly showed that stimulation of the Vagus nerve in the 
presence of severe hypovolaemia in rabbits may paradoxically induce a rise in blood 
pressure. This interpretation is supported by the dose-effect of differing levels of 
hypovolaemia. Haemodynamic decompensation in the presence of bradycardia is 
dependent on vascular reactivity.(312) The findings of Marshall et al.(9) and Oei et 
al.(224) that blood pressure increases despite bradycardia signify that increases in 
vascular resistance or ejection volume, or both, occur during intubation for neonatal 
respiratory distress. 
 
Animal experimentation suggested that blood pressure responses to electrical 
stimulation of the Vagus nerve in hypovolaemia and endotoxaemia models were 
different. This is for two reasons, firstly because the baseline levels of 
catecholamines in the endotoxin group were in excess of those in either the control or 
the hypovolaemia groups and secondly the hypovolaemic rabbits had spent a shorter 
time under anaesthetic. What can be said is that despite significantly higher levels of 
noradrenaline, which should theoretically have facilitated vasoconstriction, the fall in 
blood pressure of the endotoxaemic rabbits was similar to that of the controls. This is 
a new finding that suggests that the different pathologies may have different 
influences on haemodynamic compensation during intubation.  
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An alternative methodology to the estimation of changes in blood pressure after 
vagal stimulation would have been to measure biological markers of poor perfusion a 
posteriori. This would have involved before-and-after intubation sampling of blood 
either in a clinical or an experimental setting. Brain naturietic peptide (BNP) has 
been used to predict neurologic outcome at six months and survival following 
cardiac arrest and would be a possible candidate for investigation. However, this 
retrospective study of 155 patients recorded a median no-flow time of 2 minutes 
[IQR 2-5minutes] and a low-flow time of 16 minutes [IQR 10-25] which is in excess 
of the majority of our patients.(313)  
 
Another option would be to test for troponin I levels which are sensitive and specific 
for myocardial injury.(314-316) Cecchia et al.(315) looked at rises in troponin I in a 
prospective cohort of 24 children all of whom had had a cardiac arrest including 12 
children who had drowned or nearly-drowned. Seven of the children did not survive 
and had significantly higher levels of troponin I that those that survived. The median 
arrest time of the survivors was six minutes [IQR 3-63] compared to median 34 
minutes [IQR 4-70] for the non-survivors which is again considerably in excess of 
our patients. Also, sampling relatively large populations prior to intubation would 
have posed important ethical questions as to the benefit versus the discomfort 
involved. This methodology was not used in the experimental setting for two 
reasons. Firstly, the reductions in blood pressure typically were rarely greater than 
one half of pre-stimulation values and generally lasted two to three minutes. 
Secondly, there was considerable experimental 'noise' from repeated stimulations so 
the accuracy of any one reading related at any one stimulation would have been 
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severely compromised because clinical studies have looked production of these 
markers over time periods of hours rather than minutes.(317) 
 
9.6  The Usefulness of Atropine 
 
The fact that 80% (median 8[7-9]) of the Delphi participants used atropine according 
to their personal preference whereas only 49% (median 6[3-8]) base their decision on 
scientific literature is illustrative of how far we have (not) progressed in the 50 years 
from the opinion of Eger(1) in 1962 to Kumar in 2010.(2)  
 
"The time has come when Belladonna drugs should be  
tailored to circumstance and not given by rote" Eger 1962(1) 
 
'...[the] long-term benefits and adverse effects  
of [atropine] premedication are unknown'. Kumar et al. 2010(2) 
 
Atropine was associated with a reduction in fall in heart rate, arrhythmia and/or 
conduction disturbances. Atropine favoured progression from sinus tachycardia to 
faster sinus tachycardia without progression to ventricular tachycardia and/or 
fibrillation. In fact, we recorded no detrimental effects of atropine on the circulation.  
 
Perhaps atropine can be regarded in the same light as a vaccination; it protects from 
an event that probably will never occur. But the impact of atropine is more complex. 
Some children who received atropine continued to show bradycardia and arrhythmia, 
although at a reduced frequency. This may be as a result of insufficient time being 
left from the moment injection of atropine and the start of intubation. Alternatively, 
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the pressure on the activation of the Vagus nerve may be so intense that atropine is 
unable to overcome the stimulation or the haemodynamic state so unstable that small 
signals from the Vagus nerve may have large haemodynamic effects. 
 
The results presented in this thesis do not support the recommendations that atropine 
should be routinely used for CCI in neonates.(29, 30, 32) This is because although 
they frequently experience bradycardia, they infrequently exhibit arrhythmias and 
conduction disturbances and did not die during intubation in our ECG study. Neither 
have they been shown to occur during intubation in other studies.(224, 225) 
Neonates generally suffer from neonatal respiratory pathologies that are not 
vasoplegic and should be able to protect themselves from bradycardia by increases in 
vascular resistance and ejection volume. An important caveat to this is the group of 
extremely premature newborns. The precocious stage of neurodevelopment in this 
group means that they are possibly at risk of cranial hypertension rather than 
systemic hypotension. Both hypotension and tachycardia may be a risk for this 
important group. 
 
The situation is different in children over four weeks of age. In this group atropine 
did reduce the incidence of arrhythmias and conduction disturbances. Atropine was 
not shown to induce conversion of sinus tachycardia to ventricular tachycardia of 
fibrillation. Importantly, vasoplegic pathologies are more frequently encountered in 
this group where increasing ejection volume may be insufficient to compensate for 
bradycardia in the face of vasodilatation. Atropine may also have an influence on 
ICU mortality that is not related to its action in maintaining heart rate during 
intubation. 
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9.7  Summary of findings 
 
The Delphi group agreed that there is a risk of death during intubation but was not in 
agreement that atropine could modify this risk. Intubation mortality during first 
intubations was 0.4%, which is lower than that published for similar adult studies. 
Atropine diminished ICU mortality only in the group of children over 28 days and in 
a manner that was independent on its capacity to reduce heart rate during intubation. 
The observation may be related to beat-to-beat stabilisation of the heart rate.  
 
Hypotension occurred when the Vagus nerve was electrically stimulated under 
experimental conditions in rabbits. The degree of hypotension was reduced when the 
animals were hypovolaemic. This occurred in a dose dependent manner. 
Endotoxaemia did not change blood pressure reductions during vagal stimulation. 
The Delphi group was unable to agree that hypotension is a risk during intubation or 
that atropine reduced this risk. The Intensivists were furthermore unable to agree as 
to whether atropine should be recommended for intubations in children with septic 
shock. 
 
Sinus pause was not infrequent in both neonates and children aged over four weeks 
but the progression to the more severe conduction disturbances and ventricular 
arrhythmias was more frequent in the children aged over four weeks. Atropine was 
associated with a reduced frequency ventricular arrhythmias and conduction 
disturbances and did not induce the progression from sinus tachycardia to ventricular 
tachycardia and/or fibrillation.  
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Reductions in heart rate occur to a similar degree during critical care intubation in 
children above and below one month of age. When considering the potential for lost 
heart beats during intubation bradycardia, a fall in heart rate of less than 50 beats/min 
resulted in the loss of 25 beats or less with the exception of one child who lost 35 
beats. When the heart rate falls below 50 beats/min there is a wide variation in loss of 
beats (as much as 50 fold). Atropine was associated with reduced bradycardia in both 
age groups and numbers of lost beats but not for all children. The opinion of the 
group of Intensivists who participated in the Delphi study was that atropine did not 
prevent bradycardia.  
 
9.8  Future Directions 
 
We discovered that the frequency of death during intubation is low. If the number of 
deaths recorded in the studies of Carroll et al.(19) and Fastle and Roback (20) is 
added to the number of deaths during the two years of study we come to one death 
for 502 intubations. As such prospective cohort studies using the outcome of death 
during intubation would require very large sample sizes to investigate the risk 
factors. An alternative could be to use a case-control methodology to examine 
associated risk factors. 
 
The association between lost heart beats and haemodynamic decompensation could 
be investigated by regarding the use of adrenaline, fluid boluses, cardiac massage or 
death during intubation as 'event triggers' and the intubation ECG printed. The ECGs 
of the next five intubations could be printed as controls.  
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This thesis tries to investigate the potential effect of pathology on haemodynamic 
stability during intubation. We were frustrated by the close relationship between 
atropine prescription of attitudes to prescription in the Delphi survey, the low 
intubation mortality and raised levels of catecholamines in the endotoxaemic rabbits.  
An alternative methodology to attempt to eliminate baseline catecholamine bias 
would be to manufacture an electrode that could be surgically implanted around the 
Vagus nerve (using non-urethane anaesthesia). The tissues would be closed and the 
animal left for 48h before intubation and ventilation. Without re-opening the tissues, 
electrical stimulation of the Vagus nerve would be initiated and monitoring of 
haemodynamic parameters carried out using Doppler technology. The advantage of 
such an approach would be that the vascular resistance and cardiac output could be 
measured using an algorithm that would not be affected by simultaneous changes in 
blood pressure and heart rate.  
 
Finally, the bias that we encountered regarding low frequency of use of muscle 
relaxants and the relatively small group of Intensivists needs to be eliminated in any 
future study of ICU mortality. Our surprising result that atropine may have an 
influence on ICU mortality should be investigated by a, randomised, controlled trial. 
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 Annexe 3, 
INFORMATION AUX PARENTS 
 
Madame, Monsieur, 
 
Lors de sa réanimation dans l’Unité de Réanimation de Robert Debré ou par le 
SMUR pédiatrique, votre enfant a nécessité une assistance ventilatoire intra-
trachéale. Cette technique consiste à intuber votre enfant, c'est-à-dire à placer une 
sonde dans la gorge (trachée) afin de ventiler directement les poumons. Lors de ce 
geste, la procédure habituelle consiste à surveiller systématiquement et en continu le 
taux d’oxygène dans le sang et la fréquence des battements du cœur (fréquence 
cardiaque) afin d’assurer les conditions optimales de sécurité. Ces deux paramètres 
sont enregistrés automatiquement sur les appareils de surveillance du service de 
Réanimation et du SMUR. 
 
Nous réalisons actuellement une étude concernant les variations de la fréquence 
cardiaque pendant la pose de la sonde d’intubation. Ainsi, nous recueillons les 
enregistrements de fréquence cardiaque de tous les enfants de moins de neuf ans 
intubés par les médecins de Réanimation ou du SMUR, ce qui ne modifie en aucun 
cas la prise en charge habituelle de votre enfant dans une telle situation. Nous 
rendons ces enregistrements entièrement anonymes. Puis nous les sauvegardons dans 
une banque de données informatiques interne au service afin de les analyser.  
 
Le droit d’accès et de rectification prévu par la loi « Informatique et Liberté » 
s’exerce à tout moment auprès des responsables de l’étude. Les données sont 
protégées par les dispositions article 40 de la loi 78.17 du 6 janvier 1978 et art. 
L.111-7 du Code de Santé Publique, relative à l’informatique, aux fichiers et aux 
libertés. Elles ne pourront en aucun cas être utilisées à des fins commerciales ou de 
publicité. Le fichier de données sera détruit au terme du délai prévu à l’article 
R.1124-7 du Code de la Santé Publique.  
 
Néanmoins, vous avez le droit d’accès et de rectification des données concernant 
votre enfant.  Ce droit peut être exercé à tout moment soit directement par vous-
même, soit par l'intermédiaire du médecin de votre choix, en prenant contact avec un 
des deux investigateurs ci-dessous. 
 
Avec nos remerciements pour votre collaboration, nous vous prions d'agréer, 
Madame, Monsieur, l'assurance de notre considération distinguée. 
____________________________________________________________________
_______ 
 
Responsable de l’étude :  Docteur Peter JONES  
   SMUR Pédiatrique de l’Hôpital Robert Debré  
Chef de service :   Professeur Stéphane DAUGER  
    Service de Réanimation Pédiatriques 
    SMUR Pédiatrique de l’Hôpital Robert Debré 
 
Pôle de Pédiatrie Aiguë et Médecine Interne 
Hôpital Robert Debré 
Assistance Publique- Hôpitaux de Paris, 48 Bd Sérurier, 75019 PARIS 
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